

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number  
**WO 03/028640 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**  
(21) International Application Number: PCT/US02/30917  
(22) International Filing Date:  
27 September 2002 (27.09.2002)  
(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
60/328,123 3 October 2001 (03.10.2001) US

(71) Applicant (for all designated States except US): VAN-  
DERBILT UNIVERSITY [US/US]; Office of Technology  
Transfer, 1207 17th Avenue South, Suite 105, Nashville,  
TN 37212 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HALLAHAN,  
Dennis, E. [US/US]; 4214 Estes Road, Nashville, TN  
37215 (US). QU, Shimian [US/US]; 835 Rodney Drive,  
Nashville, TN 37205 (US).

(74) Agent: TAYLOR, Arles, A., Jr.; Jenkins & Wilson, P.A.,  
Suite 1400, University Tower, 3100 Tower Boulevard,  
Durham, NC 27707 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: *IN VIVO* PANNING FOR LIGANDS TO RADIATION-INDUCED MOLECULES

(57) Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor.



**WO 03/028640 A2**

Description

*IN VIVO* PANNING FOR LIGANDS  
TO RADIATION-INDUCED MOLECULES

Cross Reference to Related Applications

5           This application is based on and claims priority to U.S. Provisional Patent application serial number 60/328,123, filed October 3, 2001, herein incorporated by reference in its entirety.

Grant Statement

          This work was supported by grants CA58508, CA70937, CA89888,  
10 CA89674, and CA90949 from the U.S. National Institute of Health. Thus, the U.S. government has certain rights in the invention.

Field of the Invention

          The present invention generally relates to ligands for x-ray guided drug delivery. More particularly, the invention provides a method for *in vivo*  
15 panning of diverse molecules for isolation of targeting ligands that specifically bind an irradiated tumor. Also provided are novel targeting ligands identified by the panning method, and therapeutic and diagnostic uses of the same.

Table of Abbreviations

20	AR	-	autoradiography
	CPM	-	counts per minute
	CT	-	computerized tomography
	HPLC	-	high performance liquid chromatography
	IP	-	imaging plate
25	LUER	-	low energy high resolution
	MRI	-	magnetic resonance imaging
	NM	-	nuclear magnetic
	OD	-	optical density
	PCR	-	Polymerase Chain Reaction
30	PET	-	positron emission spectroscopy
	PFU	-	plaque forming unit
	ROI	-	region of interest

- 2 -

SPECT - single photon emission computed  
tomography

Background of the Invention

Tumor-specific drug delivery has the potential to minimize toxicity to  
5 normal tissues and improve the bioavailability of therapeutic agents to tumor  
cells (Hallahan *et al.*, 1995b; Arap *et al.*, 1998). Targeting ligands include  
antibodies and peptides that accumulate in tumors by specific binding to  
target molecules present on tumor vasculature, endothelial cells associated  
with tumor vasculature, and tumor cells. Effective target molecules are  
10 generally cell surface receptors or other molecules present at the exterior of  
tumor cells such that they are accessible to targeting ligands (Hallahan *et al.*, 2001a).

Existing site-specific drug delivery systems include ligands that  
recognize a tumor marker such as Her2/neu (v-erb-b2 avian erythroblastic  
15 leukemia viral oncogene homologue 2), CEA (carcinoembryonic antigen) (Ito  
*et al.*, 1991), and breast cancer antigens (Manome *et al.*, 1994; Kirpotin *et al.*,  
1997; Becerril *et al.*, 1999). *See also* PCT International Publication No.  
WO 98/10795. In an effort to identify ligands that are capable of targeting to  
multiple tumor types, targeting ligands have been developed that bind to  
20 target molecules present on tumor vasculature (Baillie *et al.*, 1995;  
Pasqualini & Ruoslahti, 1996; Arap *et al.*, 1998; Burg *et al.*, 1999; Ellerby *et al.*, 1999).

Despite these advances, current methods for targeted drug delivery  
are hindered by targeting ligands that also bind normal tissues and/or a lack  
25 of targeting ligands that bind multiple tumor types. Ideally, a targeting  
molecule should display specific targeting in the absence of substantial  
binding to normal tissues, and a capacity for targeting to a variety of tumor  
types and stages. Thus, there exists a long-felt need in the art for methods  
to achieve site-specific, tumoral delivery of therapeutic and/or diagnostic  
30 agents.

- 3 -

To meet this need, the present invention provides a method for identifying ligands that bind to irradiated tumors. Such ligands are useful for x-ray guided drug delivery, among other applications.

#### Summary of Invention

5        The present invention provides methods for identifying a molecule that binds to an irradiated tumor in a subject. In one embodiment of the invention, the method comprises: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating one or more molecules of the library from the tumor, whereby a molecule  
10       that binds an irradiated tumor is identified.

      In another embodiment of the invention, the method for identifying a molecule that binds an irradiated tumor comprises: (a) exposing a tumor and a control tissue to ionizing radiation; (b) administering to the tumor and to the control tissue a library of diverse molecules; (c) detecting one or more  
15       molecules of the library that bind to the tumor and that substantially lack binding to the control tissue, whereby a molecule that binds an irradiated tumor is identified. The method can further comprise: (a) isolating the tumor and the control tissue, and (b) administering the library to the tumor and to the control tissue *in vitro*.

20       The *in vivo* panning methods of the present invention can further comprise administering the library to isolated tumor cells or to isolated proteins prior to administering the library to a subject or to a tumor. For example, *in vitro* panning methods can be performed to select ligands that bind to particular tumor neoantigens, followed by performance of the *in vivo*  
25       panning methods as disclosed herein.

      When performing the *in vivo* panning methods of the invention, each of the steps of exposing, administering, and isolating can be repeated one or more times to modify and preferably improve ligand selection.

      A library useful for *in vivo* panning as disclosed herein can comprise  
30       in one example a library of ten or more diverse molecules, in another example a library of one hundred or more diverse molecules, and in yet another example a library of one billion or more diverse molecules.

- 4 -

Representative diverse molecules include peptides, peptide mimetics, proteins, antibodies or fragments thereof, small molecules, nucleic acids, and combinations thereof. In one embodiment of the invention, a library of peptides, antibodies, or a combination thereof is used for *in vivo* panning. A  
5 library can further comprise a library of diverse molecules that is recovered following *in vitro* panning.

Also provided are targeting ligands identified by performing the method. Representative peptide ligands are set forth as SEQ ID NOs:1-13. Also provided are cyclized and derivatized variants of peptide ligands set  
10 forth as SEQ ID NOs:1-13. Representative antibody ligands comprise single chain antibody polypeptides comprising: (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:18 or 20; (b) a polypeptide comprising an amino acid sequence substantially similar to SEQ ID NO:18 or 20; (c) a polypeptide encoded by a nucleotide sequence of SEQ ID NO:17 or 19; (d) a  
15 polypeptide encoded by a nucleotide sequence substantially similar to SEQ ID NO:17 or 19; or (e) combinations thereof. The provided peptide ligands can be used in the methods and compositions of the present invention, as disclosed herein below.

The peptide ligands of the present invention are useful for x-ray-  
20 guided delivery to a tumor in a subject. A tumor can comprise a primary or a metastasized tumor, including but not limited to a tumor selected from the group consisting of bladder carcinoma, breast carcinoma, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, gastric sarcoma, glioma, lung carcinoma, lymphoma, melanoma, multiple myeloma,  
25 osteosarcoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, stomach carcinoma, a head tumor, a neck tumor, and a solid tumor. In one example, a targeting ligand binds to an irradiated glioma, melanoma, or a Lewis Lung carcinoma.

An exemplary peptide ligand of the invention can bind to an irradiated  
30 tumor of two or more tumor types, or in another example three or more tumor types. In yet another example, a targeting ligand can bind to an irradiated glioma, melanoma, and a Lewis Lung carcinoma.

The present invention also provides a method for preparing a composition for x-ray-guided drug delivery. The method comprises: (a) performing *in vivo* panning, whereby a ligand that binds a radiation-inducible tumor molecule is identified; and (b) conjugating the ligand to a drug, 5 whereby a composition for x-ray-guided drug delivery is prepared.

The present invention thus provides a therapeutic composition, a diagnostic composition, or a combination thereof, comprising the disclosed peptide ligands. Such compositions can optionally include a drug carrier, for example a viral vector, a liposome, a plasmid, a microcapsule, and 10 combinations thereof. Drug carriers include but are not limited to liposomes and microspheres.

A diagnostic composition of the invention comprises a targeting peptide and a detectable label. A detectable label can comprise a label that can be detected *in vivo*, for example by using any one of techniques 15 including but not limited to magnetic resonance imaging, scintigraphic imaging, ultrasound, or fluorescence. When a radionuclide label is employed, for example  $^{131}\text{I}$  or  $^{99\text{m}}\text{Tc}$ , the label can be detected using PET, SPECT, gamma camera imaging, or rectilinear scanning. Alternatively, a diagnostic composition of the invention can comprise a label such as a 20 fluorophore, an epitope, or a radioactive label.

A therapeutic composition of the invention comprises a therapeutic agent and a targeting peptide. Representative therapeutic agents include a radionuclide, a cytotoxin, a therapeutic gene, and a chemotherapeutic agent. A therapeutic composition of the invention can further comprise a detectable 25 label, in one example a label that can be detected *in vivo*, to monitor the biodistribution of the composition following administration to a subject.

The present invention also provides methods for diagnosing a tumor in a subject. The method relies on the capacity of the disclosed peptide ligands to bind to an irradiated tumor. The binding reaction can be 30 performed *in vivo* or *in vitro*.

Thus, in one embodiment of the invention, a method for tumor diagnosis comprises: (a) exposing a suspected tumor to ionizing radiation;

(b) administering to the subject one or more targeting ligands identified by *in vivo* panning, wherein the one or more targeting ligands binds an irradiated tumor, and wherein the peptide comprises a detectable label; and (c) detecting the detectable label, whereby a tumor is diagnosed.

5 In another embodiment, a method for diagnosing a tumor in a subject comprises: (a) exposing a suspected tumor to ionizing radiation; (b) isolating the suspected tumor, or fraction thereof; (c) contacting the suspected tumor with one or more targeting ligands, wherein the one or more targeting ligands binds an irradiated tumor, and wherein the peptide comprises a  
10 detectable label; and (d) detecting the detectable label, whereby the tumor is diagnosed. In one example, the peptide can bind to an irradiated tumor.

For detection of a tumor *in vitro* (using an isolated tumor), the isolating can comprise biopsying a suspected tumor. The isolating can be performed prior to or subsequent to exposing the suspected tumor to  
15 ionizing radiation.

The diagnostic methods of the present invention can further comprise simultaneously detecting two or more tumors in a subject, including two or more tumors comprising two or more tumor types.

The present invention further provides a method for x-ray-guided  
20 delivery of a therapeutic composition, a diagnostic composition, and a combination thereof, to a tumor in a subject. The method comprises: (a) exposing the tumor to ionizing radiation; and (b) administering to the subject a therapeutic composition, a diagnostic composition, or a combination thereof, wherein the composition comprises a targeting ligand identified by *in vivo* panning; whereby the therapeutic composition, the diagnostic  
25 composition, or the combination thereof, is selectively targeted to the tumor.

In accordance with the methods for *in vivo* panning, tumor diagnosis, and x-ray-guided drug delivery disclosed herein, in one example an amount of radiation exposure can comprise less than about 2 Gy ionizing radiation.  
30 The invention further encompasses exposing a tumor or suspected tumor in one example to at least about 2 Gy ionizing radiation, and in another example to about 10-20 Gy ionizing radiation. In one example, a tumor is

- 7 -

irradiated 0 hours to about 24 hours, and in another example about 4 hours to about 24 hours, prior to administration to a subject of a library or a therapeutic composition, a diagnostic composition, or combination thereof.

5 The disclosed methods for tumor diagnosis and x-ray-guided drug delivery are suitable for detection and delivery of a therapeutic composition, a diagnostic composition, or a combination thereof in a warm-blooded vertebrate subject, preferably a human subject.

10 The present invention also provides a method for identifying a radiation-induced target molecule. The method comprises: (a) providing a targeting ligand identified by *in vivo* panning, wherein the peptide binds to an irradiated tumor; (b) exposing the targeting ligand to one or more candidate target molecules; and (c) determining selective binding of the one or more candidate target molecules to the targeting ligand, whereby a radiation-induced target molecule is identified. The molecule bound by the peptide  
15 can comprise a molecule present on a tumor cell, an endothelial cell associated with tumor vasculature, or a blood component. Also provided are target molecules identified by the method.

20 Accordingly, it is an object of the present invention to provide novel targeting ligands that bind irradiated tumors, methods for identifying the same, and therapeutic and/or diagnostic methods using the same. This and others objects are achieved in whole or in part by the present invention.

An object of the invention having been stated above, other objects and advantages of the present invention will become apparent to those skilled in the art after a study of the following description of the invention and  
25 non-limiting Examples.

#### Detailed Description of the Invention

##### I. Definitions

While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate  
30 explanation of the invention.

The term "ligand" as used herein refers to a molecule or other chemical entity having a capacity for binding to a target. A ligand can

comprise a peptide, an oligomer, a nucleic acid (*e.g.*, an aptamer), a small molecule (*e.g.*, a chemical compound), an antibody or fragment thereof, a nucleic acid-protein fusion, and/or any other affinity agent.

5       The term "small molecule" as used herein refers to a compound, for example an organic compound, with a molecular weight in one example of less than about 1,000 daltons, in another example less than about 750 daltons, in another example less than about 600 daltons, and in yet another example less than about 500 daltons. A small molecule also has in one example a computed log octanol-water partition coefficient in the range of  
10       about -4 to about +14, more preferably in the range of about -2 to about +7.5.

      The term "target tissue" as used herein refers to an intended site for accumulation of a ligand following administration to a subject. For example, the methods of the present invention employ a target tissue comprising an  
15       irradiated tumor.

      The term "control tissue" as used herein refers to a site suspected to substantially lack binding and/or accumulation of an administered ligand. For example, in accordance with the methods of the present invention, a non-irradiated tumor and a non-cancerous tissue are control tissues.

20       The terms "target" or "target molecule" as used herein each refer to any substance that is specifically bound by a ligand. Thus, the term "target molecule" encompasses macromolecules including but not limited to proteins, nucleic acids, carbohydrates, lipids, and complexes thereof.

      The terms "radiation-induced target" and "radiation-induced tumor  
25       target" as used herein each refer to a target molecule in a tumor whose expression, localization, or ligand-binding capacity is induced by radiation. Such a target molecule can comprise a molecule at the surface of a tumor cell, within a tumor cell, or in the extracellular matrix surrounding a tumor cell. Alternatively, a target molecule can comprise a molecule present at the  
30       surface of or within a vascular endothelial cell, or at the surface of or within a blood component such as a platelet or a leukocyte.

The term "induce", as used herein to refer to changes resulting from radiation exposure, encompasses activation of gene transcription or regulated release of proteins from cellular storage reservoirs to vascular endothelium. Alternatively, induction can refer to a process of  
5 conformational change, also called activation, such as that displayed by the glycoprotein IIb/IIIa integrin receptor upon radiation exposure (Staba *et al.*, 2000; Hallahan *et al.*, 2001a). *See also* U.S. Patent No. 6,159,443.

The terms "targeting" or "homing", as used herein to describe the *in vivo* activity of a ligand following administration to a subject, each refer to the  
10 preferential movement and/or accumulation of a ligand in a target tissue as compared with a control tissue.

The terms "selective targeting" of "selective homing" as used herein each refer to a preferential localization of a ligand that results in an amount of ligand in a target tissue that is in one example about 2-fold greater than  
15 an amount of ligand in a control tissue, in another example an amount that is about 5-fold or greater, and in yet another example an amount that is about 10-fold or greater. The terms "selective targeting" and "selective homing" also refer to binding or accumulation of a ligand in a target tissue concomitant with an absence of targeting to a control tissue, preferably the  
20 absence of targeting to all control tissues.

The term "absence of targeting" is used herein to describe substantially no binding or accumulation of a ligand in all control tissues where an amount of ligand is detectable.

The terms "targeting ligand", "targeting molecule", "homing ligand",  
25 and "homing molecule" as used herein each refer to a ligand that displays targeting activity. In one example, a targeting ligand displays selective targeting.

The term "binding" refers to an affinity between two molecules, for example, a ligand and a target molecule. As used herein, "binding" means a  
30 preferential binding of one molecule for another in a mixture of molecules. The binding of a ligand to a target molecule can be considered specific if the binding affinity is about  $1 \times 10^4 \text{ M}^{-1}$  to about  $1 \times 10^6 \text{ M}^{-1}$  or greater.

- 10 -

The phrase "specifically (or selectively) binds", when referring to the binding capacity of a ligand, refers to a binding reaction which is determinative of the presence of the protein in a heterogeneous population of proteins and other biological materials. The phrase "specifically binds" also refers to selectively targeting, as defined herein above.

The phrases "substantially lack binding" or "substantially no binding", as used herein to describe binding of a ligand in a control tissue, refers to a level of binding that encompasses non-specific or background binding, but does not include specific binding.

The term "tumor" as used herein refers to both primary and metastasized solid tumors and carcinomas of any tissue in a subject, including but not limited to breast; colon; rectum; lung; oropharynx; hypopharynx; esophagus; stomach; pancreas; liver; gallbladder; bile ducts; small intestine; urinary tract including kidney, bladder and urothelium; female genital tract including cervix, uterus, ovaries (*e.g.*, choriocarcinoma and gestational trophoblastic disease); male genital tract including prostate, seminal vesicles, testes and germ cell tumors; endocrine glands including thyroid, adrenal, and pituitary; skin (*e.g.*, hemangiomas and melanomas), bone or soft tissues; blood vessels (*e.g.*, Kaposi's sarcoma); brain, nerves, eyes, and meninges (*e.g.*, astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas and meningiomas). The term "tumor" also encompasses solid tumors arising from hematopoietic malignancies such as leukemias, including chloromas, plasmacytomas, plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia, and lymphomas including both Hodgkin's and non-Hodgkin's lymphomas.

The term "subject" as used herein refers to any invertebrate or vertebrate species. The methods of the present invention are particularly useful in the treatment and diagnosis of warm-blooded vertebrates. Thus, the invention concerns mammals and birds. More particularly contemplated is the treatment and/or diagnosis of mammals such as humans, as well as those mammals of importance due to being endangered (such as Siberian

tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Also contemplated is the treatment of birds, including the treatment of those kinds of birds that are endangered, kept in zoos, as well as fowl, and more particularly domesticated fowl, *e.g.*, poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they are also of economical importance to humans. Thus, contemplated is the treatment of livestock, including, but not limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.

The term "about", as used herein when referring to a measurable value such as an amount of weight, time, dose (*e.g.* radiation dose), etc. is meant to encompass variations of in one example  $\pm 20\%$  or  $\pm 10\%$ , in another example  $\pm 5\%$ , in another example  $\pm 1\%$ , and in yet another example  $\pm 0.1\%$  from the specified amount, as such variations are appropriate to perform the disclosed method.

## II. X-Ray Guided Drug Delivery Using Peptide Ligands

Ionizing radiation induces proteins in tumor vascular endothelium through transcriptional induction and/or posttranslational modification of cell adhesion molecules such as integrins (Hallahan *et al.*, 1995a; Hallahan *et al.*, 1996; Hallahan *et al.*, 1998; Hallahan & Virudachalam, 1999). For example, radiation induces activation of the integrin  $\alpha_{2b}\beta_3$ , also called the fibrinogen receptor, on platelets. The induced molecules can serve as binding sites for targeting ligands.

Although several radiation-induced molecules within tumor blood vessels have been identified and characterized, the  $\alpha_{2b}\beta_3$  target for drug delivery achieves the greatest site-specific peptide binding within irradiated tumor blood vessels.  $^{131}\text{I}$ -labeled fibrinogen binds specifically to tumors following exposure to ionizing radiation (U.S. Patent No. 6,159,443).

Peptides within fibrinogen that bind to the radiation-induced  $\alpha_{2b}\beta_3$  receptor include HHLGGAKQAGDV (SEQ ID NO:16) and the RGD peptide (Hallahan *et al.*, 2001a).

The present invention includes a study of the targeting activity of  $\alpha_{2b}\beta_3$  ligands in tumor-bearing subjects. Example 1 describes x-ray-guided drug delivery in animal models using ligand-conjugated liposomes and microspheres. Clinical trials using a radiolabeled  $\alpha_{2b}\beta_3$  ligand support the feasibility of x-ray-guided drug delivery in humans, as described in Example 2. See also Hallahan *et al.* (2001a) *J Control Release* 74:183-191.

Despite the successes of x-ray-guided drug delivery using  $\alpha_{2b}\beta_3$  ligands in experimental models, the clinical application of this approach is limited by nonspecific binding of the targeting ligand at sites other than the tumor (Hallahan *et al.*, 2001b). In addition, previous observations of radiation-inducible molecules have employed radiation doses that are sufficient to limit blood flow, as described in Example 3. Thus, ligands are sought that demonstrate improved tumor specificity and binding to target molecules induced by reduced radiation doses.

### III. Identification of Ligands that Bind Irradiated Tumors

Approaches for optimizing peptide binding affinity and specificity have included modification of peptide conformation and addition of flanking amino acids to extend the minimal binding motif. For example, amino acids C-terminal to the RGD sequence are differentially conserved in RGD-containing ligands, and this variation correlates with differences in binding specificity (Cheng *et al.*, 1994; Koivunen *et al.*, 1994). Similarly, cyclization of a prototype RGD peptide to restrict its conformational flexibility improved interaction of the peptide with the vitronectin receptor, yet nearly abolished interaction with the fibronectin receptor (Pierschbacher & Ruoslahti, 1987).

Despite conservation of binding motifs among ligands that bind irradiated tumors and recognition of factors that can influence ligand binding, design of peptide sequences for improved targeting activity is yet unpredictable. Approaches for identifying such peptides have therefore

relied on high volume screening methods to select effective motifs from peptide libraries (Koivunen *et al.*, 1993; Healy *et al.*, 1995). However, the utility of *in vitro*-selected peptides is unpredictable in so far as peptide binding properties are not consistently recapitulated *in vivo*. To obviate these challenges, the present invention provides a method for *in vivo* selection of targeting ligands, described further herein below.

Using the *in vivo* selection method disclosed herein, novel targeting ligands were identified that can be used for x-ray-guided drug delivery. Representative peptide ligands are set forth as SEQ ID NOs:1-13. Representative antibody ligands are set forth as SEQ ID NOs:18 and 20. The novel ligands display improved specificity of binding to irradiated tumors and are effective for targeting using low dose irradiation. The disclosed targeting ligands also offer benefits including moderate cost of preparation and ease of handling.

### 15        III.A. Libraries

As used herein, the term "library" means a collection of molecules. A library can contain a few or a large number of different molecules, varying from about ten molecules to several billion molecules or more. A molecule can comprise a naturally occurring molecule, or a synthetic molecule, which is not found in nature. Optionally, as described further herein below, a plurality of different libraries can be employed simultaneously for *in vivo* panning.

Representative libraries include but are not limited to a peptide library (U.S. Patent Nos. 6,156,511, 6,107,059, 5,922,545, and 5,223,409), an oligomer library (U.S. Patent Nos. 5,650,489 and 5,858,670), an aptamer library (U.S. Patent No. 6,180,348 and 5,756,291), a small molecule library (U.S. Patent Nos. 6,168,912 and 5,738,996), a library of antibodies or antibody fragments (U.S. Patent Nos. 6,174,708, 6,057,098, 5,922,254, 5,840,479, 5,780,225, 5,702,892, and 5,667,988), a library of nucleic acid-protein fusions (U.S. Patent No. 6,214,553), and a library of any other affinity agent that can potentially bind to an irradiated tumor (*e.g.*, U.S. Patent Nos. 5,948,635, 5,747,334, and 5,498,538).

The molecules of a library can be produced *in vitro*, or they can be synthesized *in vivo*, for example by expression of a molecule *in vivo*. Also, the molecules of a library can be displayed on any relevant support, for example, on bacterial pili (Lu *et al.*, 1995) or on phage (Smith, 1985).

5       A library can comprise a random collection of molecules. Alternatively, a library can comprise a collection of molecules having a bias for a particular sequence, structure, or conformation. *See e.g.*, U.S. Patent Nos. 5,264,563 and 5,824,483. Methods for preparing libraries containing diverse populations of various types of molecules are known in the art, for  
10       example as described in U.S. Patents cited herein above. Numerous libraries are also commercially available.

In one embodiment of the invention, a peptide library can be used to perform the disclosed *in vivo* panning methods. In one example, a peptide library comprises peptides comprising three or more amino acids, in another  
15       example at least five, six, seven, or eight amino acids, in another example up to 50 amino acids or 100 amino acids, and in yet another example up to about 200 to 300 amino acids.

The peptides can be linear, branched, or cyclic, and can include nonpeptidyl moieties. The peptides can comprise naturally occurring amino  
20       acids, synthetic amino acids, genetically encoded amino acids, non-genetically encoded amino acids, and combinations thereof.

A biased peptide library can also be used, a biased library comprising peptides wherein one or more (but not all) residues of the peptides are constant. For example, an internal residue can be constant, so that the  
25       peptide sequence is represented as:

$$(Xaa_1)_m - (AA)_1 - (Xaa_2)_n$$

where  $Xaa_1$  and  $Xaa_2$  are any amino acid, or any amino acid except cysteine, wherein  $Xaa_1$  and  $Xaa_2$  are the same or different amino acids,  $m$  and  $n$  indicate a number  $Xaa$  residues, wherein  $m$  and  $n$  are independently  
30       chosen from the range of 2 residues to 20 residues, more preferably  $m$  and  $n$  are chosen from the range of 4 residues to 9 residues, and  $AA$  is the same amino acid for all peptides in the library. In one example,  $AA$  is located at or

- 15 -

near the center of the peptide. More specifically, in one example  $m$  and  $n$  are not different by more than 2 residues; in another example  $m$  and  $n$  are equal.

The most preferred libraries are those in which AA is tryptophan, proline, or tyrosine. Second most preferred are those in which AA is phenylalanine, histidine, arginine, aspartate, leucine, or isoleucine. Third most preferred are those in which AA is asparagine, serine, alanine, or methionine. The least preferred libraries are those in which AA is cysteine or glycine.

10 A biased library used for *in vivo* panning also includes a library comprising molecules previously selected by *in vitro* panning methods. See Example 8.

In a preferred embodiment of the invention, the method for *in vivo* panning is performed using a phage peptide library. Phage display is a method to discover peptide ligands while minimizing and optimizing the structure and function of proteins. Phage are used as a scaffold to display recombinant libraries of peptides and provide a means to recover and amplify the peptides that bind to putative receptor molecules *in vivo*. *In vivo* phage selection simultaneously provides positive and subtractive screens based on the spatial separation of normal tissues and tumors. Phage that specifically bind the vasculature of normal tissues are removed while specific phage that bind target molecules present in irradiated tumors are enriched through serial rounds of biopanning.

The T7 phage has an icosahedral capsid made of 415 proteins encoded by gene 10 during its lytic phase. The T7 phage display system has the capacity to display peptides up to 15 amino acids in size at a high copy number (415 per phage). Unlike filamentous phage display systems, peptides displayed on the surface of T7 phage are not capable of peptide secretion. T7 phage also replicate more rapidly and are extremely robust when compared to other phage. The stability allows for biopanning selection procedures that require persistent phage infectivity. Accordingly, the use of T7-based phage display is an aspect of a preferred embodiment of the

present invention. Example 4 describes a representative method for preparation of a T7 phage peptide library that can be used to perform the *in vivo* panning methods disclosed herein.

5 A phage peptide library to be used in accordance with the panning methods of the present invention can also be constructed in a filamentous phage, for example M13 or M13-derived phage. Preferably, the encoded antibodies are displayed at the exterior surface of the phage, for example by fusion to M13 vital protein 8. Methods for preparing M13 libraries can be found in Sambrook & Russell (2001) Molecular Cloning: A Laboratory  
10 Manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, among other places.

In another preferred embodiment of the invention, the method for *in vivo* panning is performed using a phage antibody library, as described in Example 8. Such a library can be constructed, for example, in M13 or M13-  
15 derived phage. See e.g., U.S. Patent Nos. 6,225,447; 5,580,717; 5,702,892.

### III.B. In Vivo Panning for Ligands that Bind Irradiated Tumors

The present invention provides a method for *in vivo* panning for ligands that bind irradiated tumors. As used herein, the term "*in vivo* panning" refers to a method of screening a library for selection of a ligand  
20 that homes to an irradiated tumor.

The term "*in vivo*", as used herein to describe methods of panning or ligand selection, refers to contacting of one or more ligands to endogenous candidate target molecules, wherein the candidate target molecules are naturally present in a subject or a tumor biopsy from a subject, and the  
25 contacting occurs in the subject or in the biopsied tumor. By contrast, "*in vitro*" panning refers to contacting a library of candidate ligands with one or more isolated or recombinantly produced target molecules.

Thus, a method for *in vivo* panning as disclosed herein includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a  
30 subject a library of diverse molecules; (c) procuring the tumor or fraction thereof; and (d) isolating one or more molecules of the library of diverse molecules from the tumor, whereby a molecule that binds an irradiated

- 17 -

tumor is identified. Each step of the method can be sequentially repeated to facilitate ligand selection.

The term "administering to a subject", when used to describe provision of a library of molecules, is used in its broadest sense to mean that  
5 the library is delivered to the irradiated tumor. For example, a library can be provided to the circulation of the subject by injection or cannulization such that the molecules can pass through the tumor.

Alternatively or in addition, a library can be administered to an isolated tumor or tumor biopsy. Thus, a method for *in vivo* panning can also  
10 comprise: (a) exposing a tumor and a control tissue to ionizing radiation; (b) administering to the tumor and to the control tissue a library of diverse molecules; (c) detecting one or more molecules of the library that bind to the tumor and that substantially lack binding to the control tissue, whereby a molecule that binds an irradiated tumor is identified.

15 The *in vivo* panning methods of the present invention can further comprise administering the library to isolated tumor cells or to isolated proteins prior to administering the library to a subject or to a tumor. For example, *in vitro* panning methods can be performed to select ligands that bind to particular tumor neoantigens, followed by performance of the *in vivo*  
20 panning methods as disclosed herein.

In a preferred embodiment of the invention, the radiation treatment comprises administration of less than about 2 Gy ionizing radiation. In another preferred embodiment, the radiation treatment comprises at least about 2 Gy ionizing radiation, optionally about 2 Gy to about 3 Gy ionizing  
25 radiation, or about 2 Gy to about 6 Gy ionizing radiation. In an alternative preferred embodiment, radiation treatment comprises about 10 Gy to about 20 Gy ionizing radiation.

The methods of the present invention can be performed using any tumor-bearing subject or any subject suspected of having a tumor.  
30 Preferably a subject is a warm-blooded vertebrate, more preferably a mammal, and even more preferably a human.

In one embodiment of the invention, a library is administered to a tumor-bearing human subject following irradiation of the tumor. Methods and appropriate doses for administration of a library to a human subject are described in PCT International Publication No. WO 01/09611.

5        Example 5 describes a representative procedure for *in vivo* panning of phage-displayed peptide ligands that bind to irradiated tumor vessels in accordance with the present invention. Briefly, peptide binding was studied in tumor blood vessels of 2 distinct tumor models: (1) GL261 glioma, and (2) Lewis lung carcinoma. Tumors were irradiated with 3 Gy to facilitate  
10       identification of peptide sequences that bind tumors exposed to a minimal dose of ionizing radiation. Phage were administered by tail vein injection into tumor bearing mice following irradiation. Phage were recovered from the tumor thereafter. Following multiple rounds of sequential *in vivo* binding to irradiated tumors, phage were recovered and individual phage were  
15       randomly picked and sequenced. Recovered phage were additionally tested for targeting activity in an animal model of melanoma, as described in Example 6.

Example 8 describes a representative procedure for *in vivo* panning of phage-displayed ligands comprising single chain antibodies. The library  
20       used for *in vivo* panning was a biased library in that a pool of antibody ligands that bind to radiation-induced antigens were pre-selected *in vitro*.

### III.C. Recovery of Targeting Ligands

Methods for identifying targeting ligands that bind an irradiated tumor are selected based on one or more characteristics common to the molecules  
25       present in the library. For example, mass spectrometry and/or gas chromatography can be used to resolve molecules that home to an irradiated tumor. Thus, where a library comprises diverse molecules based generally on the structure of an organic molecule, determining the presence of a parent peak for the particular molecule can identify a ligand that binds a  
30       radiation-induced target molecule.

If desired, a molecule can be linked to a tag, which can facilitate recovery or identification of the molecule. A representative tag is an

- 19 -

oligonucleotide or a small molecule such as biotin. See e.g., Brenner & Lerner (1992) *Proc Natl Acad Sci U S A* 89:5381-5383 and U.S. Patent No. 6,068,829. In addition, a tag can be a support or surface to which a molecule can be attached. For example, a support can be a biological tag  
5 such as a virus or virus-like particle such as a bacteriophage ("phage"); a bacterium; or a eukaryotic cell such as yeast, an insect cell, or a mammalian cell (e.g., an endothelial progenitor cell or a leukocyte); or can be a physical tag such as a liposome or a microbead. A support should preferably have a diameter less than about 10  $\mu\text{m}$  to about 50  $\mu\text{m}$  in its shortest dimension,  
10 such that the support can pass relatively unhindered through the capillary beds present in the subject and not occlude circulation. In addition, a support can be nontoxic and biodegradable, particularly where the subject used for *in vivo* panning is not sacrificed for isolation of library molecules from the tumor. Where a molecule is linked to a support, the part of the  
15 molecule suspected of being able to interact with a target in a cell in the subject is preferably positioned so as be able to participate in the interaction.

#### III.D. Peptide Ligands

A targeting peptide of the present invention can be subject to various changes, substitutions, insertions, and deletions where such changes  
20 provide for certain advantages in its use. Thus, the term "peptide" encompasses any of a variety of forms of peptide derivatives, that include amides, conjugates with proteins, cyclized peptides, polymerized peptides, conservatively substituted variants, analogs, fragments, peptoids, chemically modified peptides, and peptide mimetics. The terms "targeting peptide" or  
25 "peptide ligand" each refer to a peptide as defined herein above that binds to an irradiated tumor.

Peptides of the invention can comprise naturally occurring amino acids, synthetic amino acids, genetically encoded amino acids, non-genetically encoded amino acids, and combinations thereof. Peptides can  
30 include both L-form and D-form amino acids.

- 20 -

Representative non-genetically encoded amino acids include but are not limited to 2-aminoadipic acid; 3-aminoadipic acid;  $\beta$ -aminopropionic acid; 2-aminobutyric acid; 4-aminobutyric acid (piperidinic acid); 6-aminocaproic acid; 2-aminoheptanoic acid; 2-aminoisobutyric acid; 3-aminoisobutyric acid; 5 2-aminopimelic acid; 2,4-diaminobutyric acid; desmosine; 2,2'-diaminopimelic acid; 2,3-diaminopropionic acid; N-ethylglycine; N-ethylasparagine; hydroxylysine; allo-hydroxylysine; 3-hydroxyproline; 4-hydroxyproline; isodesmosine; allo-isoleucine; N-methylglycine (sarcosine); N-methylisoleucine; N-methylvaline; norvaline; norleucine; and ornithine.

10 Representative derivatized amino acids include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or 15 other types of esters or hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine can be derivatized to form N-im-benzylhistidine.

The term "conservatively substituted variant" refers to a peptide comprising an amino acid residue sequence to a sequence of a reference 20 ligand of radiation inducible target in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the targeting activity as described herein. The phrase "conservatively substituted variant" also includes peptides wherein a residue is replaced with a chemically derivatized residue, provided that the resulting 25 peptide displays targeting activity as disclosed herein.

Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another; the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and 30 asparagine, between glycine and serine; the substitution of one basic

residue such as lysine, arginine or histidine for another; or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another.

Peptides of the present invention also include peptides comprising one or more additions and/or deletions or residues relative to the sequence of a peptide whose sequence is disclosed herein, so long as the requisite  
5 targeting activity of the peptide is maintained. The term "fragment" refers to a peptide comprising an amino acid residue sequence shorter than that of a peptide disclosed herein.

Additional residues can also be added at either terminus of a peptide  
10 for the purpose of providing a "linker" by which the peptides of the present invention can be conveniently affixed to a label or solid matrix, or carrier. Amino acid residue linkers are usually at least one residue and can be 40 or more residues, more often 1 to 10 residues, but do alone not constitute radiation inducible target ligands. Typical amino acid residues used for  
15 linking are tyrosine, cysteine, lysine, glutamic and aspartic acid, or the like. In addition, a peptide can be modified by terminal-NH<sub>2</sub> acylation (e.g., acetylation, or thioglycolic acid amidation) or by terminal-carboxylamidation (e.g., with ammonia, methylamine, and the like terminal modifications). Terminal modifications are useful, as is well known, to reduce susceptibility  
20 by proteinase digestion, and therefore serve to prolong half life of the peptides in solutions, particularly biological fluids where proteases can be present.

Peptide cyclization is also a useful terminal modification, and is particularly preferred also because of the stable structures formed by  
25 cyclization and in view of the biological activities observed for such cyclic peptides as described herein. An exemplary method for cyclizing peptides is described by Schneider & Eberle (1993) Peptides, 1992 : proceedings of the Twenty-Second European Peptide Symposium, September 13-19, 1992, Interlaken, Switzerland, Escom, Leiden. Typically, tertbutoxycarbonyl  
30 protected peptide methyl ester is dissolved in methanol and sodium hydroxide solution are added and the admixture is reacted at 20°C to hydrolytically remove the methyl ester protecting group. After evaporating

the solvent, the tertbutoxycarbonyl protected peptide is extracted with ethyl acetate from acidified aqueous solvent. The tertbutoxycarbonyl protecting group is then removed under mildly acidic conditions in dioxane cosolvent. The unprotected linear peptide with free amino and carboxyl termini so  
5 obtained is converted to its corresponding cyclic peptide by reacting a dilute solution of the linear peptide, in a mixture of dichloromethane and dimethylformamide, with dicyclohexylcarbodiimide in the presence of 1-hydroxybenzotriazole and N-methylmorpholine. The resultant cyclic peptide is then purified by chromatography.

10       The term "peptoid" as used herein refers to a peptide wherein one or more of the peptide bonds are replaced by pseudopeptide bonds including but not limited to a carba bond ( $\text{CH}_2\text{-CH}_2$ ), a depsi bond ( $\text{CO-O}$ ), a hydroxyethylene bond ( $\text{CHOH-CH}_2$ ), a ketomethylene bond ( $\text{CO-CH}_2$ ), a methylene-oxy bond ( $\text{CH}_2\text{-O}$ ), a reduced bond ( $\text{CH}_2\text{-NH}$ ), a thiomethylene  
15 bond ( $\text{CH}_2\text{-S}$ ), a thiopeptide bond ( $\text{CS-NH}$ ), and an N-modified bond ( $\text{-NRCO-}$ ). See e.g. Corringier *et al.* (1993) *J Med Chem* 36:166-172; Garbay-Jaureguiberry *et al.* (1992) *Int J Pept Protein Res* 39:523-527; Tung *et al.* (1992) *Pept Res* 5:115-118; Urge *et al.* (1992) *Carbohydr Res* 235:83-93; Pavone *et al.* (1993) *Int J Pept Protein Res* 41:15-20.

20       Peptides of the present invention, including peptoids, can be synthesized by any of the techniques that are known to those skilled in the art of peptide synthesis. Synthetic chemistry techniques, such as a solid-phase Merrifield-type synthesis, are preferred for reasons of purity, antigenic specificity, freedom from undesired side products, ease of production and  
25 the like. A summary of representative techniques can be found in Stewart & Young (1969) Solid Phase Peptide Synthesis. Freeman, San Francisco; Merrifield (1969) *Adv Enzymol Relat Areas Mol Biol* 32:221-296; Fields & Noble (1990) *Int J Pept Protein Res* 35:161-214; and Bodanszky (1993) Principles of Peptide Synthesis. 2nd rev. ed. Springer-Verlag, Berlin; New  
30 York. Solid phase synthesis techniques can be found in Andersson *et al.* (2000) *Biopolymers* 55:227-250, references cited therein, and in U.S. Patent Nos. 6,015,561, 6,015,881, 6,031,071, and 4,244,946. Peptide synthesis in

solution is described by Schröder & Lübke (1965) The Peptides. Academic Press, New York. Appropriate protective groups usable in such synthesis are described in the above texts and in McOmie (1973) Protective Groups in Organic Chemistry. Plenum Press, London, New York. Peptides that include  
5 naturally occurring amino acids can also be produced using recombinant DNA technology. In addition, peptides comprising a specified amino acid sequence can be purchased from commercial sources (*e.g.*, Biopeptide Co., LLC of San Diego, California and PeptidoGenics of Livermore, California).

The term "peptide mimetic" as used herein refers to a ligand that  
10 mimics the biological activity of a reference peptide, by substantially duplicating the targeting activity of the reference peptide, but it is not a peptide or peptoid. Preferably, a peptide mimetic has a molecular weight of less than about 700 daltons.

A peptide mimetic can be designed by: (a) identifying the  
15 pharmacophoric groups responsible for the targeting activity of a peptide; (b) determining the spatial arrangements of the pharmacophoric groups in the active conformation of the peptide; and (c) selecting a pharmaceutically acceptable template upon which to mount the pharmacophoric groups in a manner that allows them to retain their spatial arrangement in the active  
20 conformation of the peptide. For identification of pharmacophoric groups responsible for targeting activity, mutant variants of the peptide can be prepared and assayed for targeting activity. Alternatively or in addition, the three-dimensional structure of a complex of the peptide and its target molecule can be examined for evidence of interactions, for example the fit of  
25 a peptide side chain into a cleft of the target molecule, potential sites for hydrogen bonding, etc. The spatial arrangements of the pharmacophoric groups can be determined by NMR spectroscopy or X-ray diffraction studies. An initial three-dimensional model can be refined by energy minimization and molecular dynamics simulation. A template for modeling can be  
30 selected by reference to a template database and will typically allow the mounting of 2-8 pharmacophores. A peptide mimetic is identified wherein

addition of the pharmacophoric groups to the template maintains their spatial arrangement as in the peptide.

A peptide mimetic can also be identified by assigning a hashed bitmap structural fingerprint to the peptide based on its chemical structure, and determining the similarity of that fingerprint to that of each compound in a broad chemical database. The fingerprints can be determined using fingerprinting software commercially distributed for that purpose by Daylight Chemical Information Systems, Inc. (Mission Viejo, California) according to the vendor's instructions. Representative databases include but are not limited to SPREI'95 (InfoChem GmbH of München, Germany), Index Chemicus (ISI of Philadelphia, Pennsylvania), World Drug Index (Derwent of London, United Kingdom), TSCA93 (United States Environmental Protection Agency), MedChem (Biobyte of Claremont, California), Maybridge Organic Chemical Catalog (Maybridge of Cornwall, England), Available Chemicals Directory (MDL Information Systems of San Leandro, California), NCI96 (United States National Cancer Institute), Asinex Catalog of Organic Compounds (Asinex Ltd. of Moscow, Russia), and NP (InterBioScreen Ltd. of Moscow, Russia). A peptide mimetic of a reference peptide is selected as comprising a fingerprint with a similarity (Tanamoto coefficient) of at least 0.85 relative to the fingerprint of the reference peptide. Such peptide mimetics can be tested for bonding to an irradiated tumor using the methods disclosed herein.

Additional techniques for the design and preparation of peptide mimetics can be found in U.S. Patent Nos. 5,811,392; 5,811,512; 5,578,629; 5,817,879; 5,817,757; and 5,811,515.

Any peptide or peptide mimetic of the present invention can be used in the form of a pharmaceutically acceptable salt. Suitable acids which are capable of the peptides with the peptides of the present invention include inorganic acids such as trifluoroacetic acid (TFA), hydrochloric acid (HCl), hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic

- 25 -

acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid or the like. HCl and TFA salts are particularly preferred.

Suitable bases capable of forming salts with the peptides of the present invention include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-di- and tri-alkyl and aryl amines (e.g. triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like), and optionally substituted ethanolamines (e.g. ethanolamine, diethanolamine and the like).

### III.E. Antibody Ligands

10 An targeting antibody of the present invention comprises an antibody identified by the *in vivo* panning methods disclosed herein. Preferably, an antibody targeting ligand comprises: (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:18 or 20; (b) a polypeptide substantially identical to SEQ ID NO:18 or 20; (c) a polypeptide encoded by SEQ ID  
15 NO:17 or 19; or (d) a polypeptide substantially identical to SEQ ID NO:17 or 19. Thus, the present invention also provides an isolated nucleic acid that encodes an antibody targeting ligand comprising: (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:17 or 19; or (b) a nucleic acid molecule substantially identical to SEQ ID NO:17 or 19.

20 The term "isolated", as used in the context of a nucleic acid or polypeptide, indicates that the nucleic acid or polypeptide exists apart from its native environment and is not a product of nature. An isolated nucleic acid or polypeptide can exist in a purified form or can exist in a non-native environment such as a transgenic host cell.

25 Nucleic Acids Encoding Targeting Antibodies. The terms "nucleic acid molecule" or "nucleic acid" each refer to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar properties as the  
30 reference natural nucleic acid. The terms "nucleic acid molecule" or "nucleic acid" can also be used in place of "gene", "cDNA", or "mRNA". Nucleic acids

can be synthesized, or can be derived from any biological source, including any organism.

The term "substantially identical", as used herein to describe a degree of similarity between nucleotide sequences, refers to two or more sequences that have at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably about 90% to about 99%, still more preferably about 95% to about 99%, and most preferably about 99% nucleotide identity, as measured using one of the following sequence comparison algorithms (described herein below) or by visual inspection. Preferably, the substantial identity exists in nucleotide sequences of at least about 100 residues, more preferably in nucleotide sequences of at least about 150 residues, and most preferably in nucleotide sequences comprising a full length coding sequence.

Thus, substantially identical sequences can comprise mutagenized sequences, including sequences comprising silent mutations, or variably synthesized sequences. A mutation or variant sequence can comprise a single base change.

Another indication that two nucleotide sequences are substantially identical is that the two molecules specifically or substantially hybridize to each other under stringent conditions. In the context of nucleic acid hybridization, two nucleic acid sequences being compared can be designated a "probe" and a "target". A "probe" is a reference nucleic acid molecule, and a "target" is a test nucleic acid molecule, often found within a heterogeneous population of nucleic acid molecules. A "target sequence" is synonymous with a "test sequence".

A preferred nucleotide sequence employed for hybridization studies or assays includes probe sequences that are complementary to or mimic at least an about 14 to 40 nucleotide sequence of a nucleic acid molecule of the present invention. For this purpose, a probe comprises a region of the nucleic acid molecule other than a sequence encoding a common immunoglobulin region. Thus, a probe preferably comprises a sequence encoding a domain of the antibody that comprises an antigen binding site.

Preferably, probes comprise 14 to 20 nucleotides, or even longer where desired, such as 30, 40, 50, 60, 100, 200, 300 nucleotides or up to the full length of a region of SEQ ID NO:17 or 19 that encodes an antigen binding site. Such fragments can be readily prepared by, for example, chemical  
5 synthesis of the fragment, by application of nucleic acid amplification technology, or by introducing selected sequences into recombinant vectors for recombinant production.

The phrase "hybridizing specifically to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide  
10 sequence under stringent conditions when that sequence is present in a complex nucleic acid mixture (e.g., total cellular DNA or RNA).

The phrase "hybridizing substantially to" refers to complementary hybridization between a probe nucleic acid molecule and a target nucleic acid molecule and embraces minor mismatches that can be accommodated  
15 by reducing the stringency of the hybridization media to achieve the desired hybridization.

"Stringent hybridization conditions" and "stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments such as Southern and Northern blot analysis are both sequence- and environment-  
20 dependent. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology- Hybridization with Nucleic Acid Probes, part I chapter 2, Elsevier, New York, New York. Generally, highly stringent hybridization and wash conditions are  
25 selected to be about 5°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. Typically, under "stringent conditions" a probe will hybridize specifically to its target subsequence, but to no other sequences.

The  $T_m$  is the temperature (under defined ionic strength and pH) at  
30 which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the  $T_m$  for a particular probe. An example of stringent hybridization conditions for Southern or

Northern Blot analysis of complementary nucleic acids having more than about 100 complementary residues is overnight hybridization in 50% formamide with 1 mg of heparin at 42°C. An example of highly stringent wash conditions is 15 minutes in 0.1X SSC at 65°C. An example of stringent wash conditions is 15 minutes in 0.2X SSC buffer at 65°C. See Sambrook *et al.*, eds (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York for a description of SSC buffer. Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example of medium stringency wash conditions for a duplex of more than about 100 nucleotides, is 15 minutes in 1X SSC at 45°C. An example of low stringency wash for a duplex of more than about 100 nucleotides, is 15 minutes in 4X to 6X SSC at 40°C. For short probes (*e.g.*, about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1M Na<sup>+</sup> ion, typically about 0.01 to 1M Na<sup>+</sup> ion concentration (or other salts) at pH 7.0-8.3, and the temperature is typically at least about 30°C. Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. In general, a signal to noise ratio of 2-fold (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

The following are examples of hybridization and wash conditions that can be used to identify nucleotide sequences that are substantially identical to reference nucleotide sequences of the present invention: a probe nucleotide sequence preferably hybridizes to a target nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5M NaPO<sub>4</sub>, 1mM EDTA at 50°C followed by washing in 2X SSC, 0.1% SDS at 50°C; more preferably, a probe and target sequence hybridize in 7% sodium dodecyl sulfate (SDS), 0.5M NaPO<sub>4</sub>, 1mM EDTA at 50°C followed by washing in 1X SSC, 0.1% SDS at 50°C; more preferably, a probe and target sequence hybridize in 7% sodium dodecyl sulfate (SDS), 0.5M NaPO<sub>4</sub>, 1mM EDTA at 50°C followed by washing in 0.5X SSC, 0.1% SDS at 50°C; more preferably, a probe and target sequence hybridize in 7% sodium dodecyl sulfate (SDS), 0.5M

NaPO<sub>4</sub>, 1mM EDTA at 50°C followed by washing in 0.1X SSC, 0.1% SDS at 50°C; more preferably, a probe and target sequence hybridize in 7% sodium dodecyl sulfate (SDS), 0.5M NaPO<sub>4</sub>, 1mM EDTA at 50°C followed by washing in 0.1X SSC, 0.1% SDS at 65°C.

5           A further indication that two nucleic acid sequences are substantially identical is that proteins encoded by the nucleic acids are substantially identical, share an overall three-dimensional structure, or are biologically functional equivalents. These terms are defined further herein below. Nucleic acid molecules that do not hybridize to each other under stringent  
10 conditions are still substantially identical if the corresponding proteins are substantially identical. This can occur, for example, when two nucleotide sequences are significantly degenerate as permitted by the genetic code.

          The term "conservatively substituted variants" refers to nucleic acid sequences having degenerate codon substitutions wherein the third position  
15 of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues. See Batzer *et al.* (1991) *Nucleic Acids Res* 19:5081; Ohtsuka *et al.* (1985) *J Biol Chem* 260:2605-2608; Rossolini *et al.* (1994) *Mol Cell Probes* 8:91-98

          The term "subsequence" refers to a sequence of nucleic acids that  
20 comprises a part of a longer nucleic acid sequence. An exemplary subsequence is a probe, described herein above, or a primer. The term "primer" as used herein refers to a contiguous sequence comprising about 8 or more deoxyribonucleotides or ribonucleotides, preferably 10-20 nucleotides, and more preferably 20-30 nucleotides of a selected nucleic  
25 acid molecule. The primers of the invention encompass oligonucleotides of sufficient length and appropriate sequence so as to provide initiation of polymerization on a nucleic acid molecule of the present invention.

          The term "elongated sequence" refers to an addition of nucleotides (or other analogous molecules) incorporated into the nucleic acid. For  
30 example, a polymerase (*e.g.*, a DNA polymerase) can add sequences at the 3' terminus of the nucleic acid molecule. In addition, the nucleotide sequence can be combined with other DNA sequences, such as promoters,

promoter regions, enhancers, polyadenylation signals, intronic sequences, additional restriction enzyme sites, multiple cloning sites, and other coding segments.

Nucleic acids of the present invention can be cloned, synthesized, 5 recombinantly altered, mutagenized, or combinations thereof. Standard recombinant DNA and molecular cloning techniques used to isolate nucleic acids are known in the art. Site-specific mutagenesis to create base pair changes, deletions, or small insertions are also known in the art. See e.g., Sambrook *et al.* (eds.) (1989) Molecular Cloning: A Laboratory Manual. Cold 10 Spring Harbor Laboratory Press, Cold Spring Harbor; Silhavy *et al.* (1984) Experiments with Gene Fusions. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Glover & Hames (1995) DNA Cloning: A Practical Approach, 2nd ed. IRL Press at Oxford University Press, Oxford/New York; Ausubel (ed.) (1995) Short Protocols in Molecular Biology, 3rd ed. Wiley, 15 New York.

Single Chain Antibody Polypeptides. The term "substantially identical", as used herein to describe a level of similarity between a polypeptide comprising an antibody targeting ligand and a polypeptide to SCN1A, refers to a sequence having at least about 45%, more preferably at 20 least about 50%, still more preferably at least about 60%, still more preferably at least about 70%, still more preferably at least about 80%, still more preferably at least about 90%, still more preferably at least about 95%, and still more preferably at least about 99% sequence identity to SEQ ID NO:17 or 19, when compared over the full length of the single chain 25 polypeptide. The term "full length", as used herein to describe an antibody targeting ligand, comprises an amino acid sequence having 254 amino acids. Methods for determining percent identity are defined herein below.

Substantially identical polypeptides also encompass two or more polypeptides sharing a conserved three-dimensional structure. 30 Computational methods can be used to compare structural representations, and structural models can be generated and easily tuned to identify similarities around important active sites or ligand binding sites. See Saqi *et*

*al.* (1999) *Bioinformatics* 15:521-522; Barton (1998) *Acta Crystallogr D Biol Crystallogr* 54:1139-1146; Henikoff *et al.* (2000) *Electrophoresis* 21:1700-1706; Huang *et al.* (2000) *Pac Symp Biocomput*:230-241.

Substantially identical proteins also include proteins comprising an amino acid sequence comprising amino acids that are functionally equivalent to amino acids of SEQ ID NOs:18 and 20. The term "functionally equivalent" in the context of amino acid sequences is known in the art and is based on the relative similarity of the amino acid side-chain substituents. See Henikoff & Henikoff (2000) *Adv Protein Chem* 54:73-97. Relevant factors for consideration include side-chain hydrophobicity, hydrophilicity, charge, and size. For example, arginine, lysine, and histidine are all positively charged residues; that alanine, glycine, and serine are all of similar size; and that phenylalanine, tryptophan, and tyrosine all have a generally similar shape. By this analysis, described further herein below, arginine, lysine, and histidine; alanine, glycine, and serine; and phenylalanine, tryptophan, and tyrosine; are defined herein as biologically functional equivalents.

In making biologically functional equivalent amino acid substitutions, the hydrophathic index of amino acids can be considered. Each amino acid has been assigned a hydrophathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+ 4.5); valine (+ 4.2); leucine (+ 3.8); phenylalanine (+ 2.8); cysteine (+ 2.5); methionine (+ 1.9); alanine (+ 1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

The importance of the hydrophathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte *et al.*, 1982). It is known that certain amino acids can be substituted for other amino acids having a similar hydrophathic index or score and still retain a similar biological activity. In making changes based upon the hydrophathic index, the substitution of amino acids whose hydrophathic indices are within  $\pm 2$  of the original value is preferred, those which are within  $\pm 1$  of

- 32 -

the original value are particularly preferred, and those within  $\pm 0.5$  of the original value are even more particularly preferred.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent No. 4,554,101 describes that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, *e.g.*, with a biological property of the protein. It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent protein.

As detailed in U.S. Patent No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+ 3.0); lysine (+ 3.0); aspartate (+ 3.0 $\pm$ 1); glutamate (+ 3.0 $\pm$ 1); serine (+ 0.3); asparagine (+ 0.2); glutamine (+ 0.2); glycine (0); threonine (-0.4); proline (-0.5 $\pm$ 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$  of the original value is preferred, those which are within  $\pm 1$  of the original value are particularly preferred, and those within  $\pm 0.5$  of the original value are even more particularly preferred.

The term "substantially identical" also encompasses polypeptides that are biologically functional equivalents. The term "functional", as used herein to describe polypeptides comprising antibody targeting ligands, refers two or more antibodies that are immunoreactive with a same radiation-induced target molecule. Preferably, the two or more antibodies specifically bind a same target molecule and substantially lack binding to a control antigen.

The term "specifically binds", when used to describe binding of an antibody to a target molecule, refers to binding to a target molecule in a heterogeneous mixture of other polypeptides.

- 33 -

The phrases "substantially lack binding" or "substantially no binding", as used herein to describe binding of an antibody to a control polypeptide or sample, refers to a level of binding that encompasses non-specific or background binding, but does not include specific binding.

5           Techniques for detecting antibody-target molecule complexes are known in the art and include but are not limited to centrifugation, affinity chromatography and other immunochemical methods. Preferably, an antibody-target molecule complex can be detected following administration of an antibody to a subject as described in Examples 6 and 7. Also  
10       preferably, an antibody-target molecule complex can be detected *in vivo* by performing radiation-guided drug delivery, wherein the drug comprises a targeting antibody of SEQ ID NO:18 or 20 and a detectable label, as described in Examples 1 and 2. *See also*, Manson (1992) Immunochemical Protocols. Humana Press, Totowa, New Jersey; Ishikawa (1999)  
15       Ultrasensitive and Rapid Enzyme Immunoassay. Elsevier, Amsterdam; New York; Law (1996) Immunoassay: A Practical Guide.

The present invention also provides functional fragments of a antibody targeting polypeptide. Such functional portion need not comprise all or substantially all of the amino acid sequence of SEQ ID NO:18 or 20.

20           The present invention also includes functional polypeptide sequences that are longer sequences than that of SEQ ID NO:18 or 20. For example, one or more amino acids can be added to the N-terminus or C-terminus of a antibody targeting ligand. Methods of preparing such proteins are known in the art.

25           Isolated polypeptides and recombinantly produced polypeptides can be purified and characterized using a variety of standard techniques that are known to the skilled artisan. *See e.g.*, Schröder & Lübke (1965) The Peptides. Academic Press, New York; Schneider & Eberle (1993) Peptides, 1992: Proceedings of the Twenty-Second European Peptide Symposium, September 13-19, 1992, Interlaken, Switzerland. Escom, Leiden; Bodanszky  
30       (1993) Principles of Peptide Synthesis, 2nd rev. ed. Springer-Verlag, Berlin;

New York; Ausubel (ed.) (1995) Short Protocols in Molecular Biology, 3rd ed. Wiley, New York.

Nucleotide and Amino Acid Sequence Comparisons. The terms "identical" or percent "identity" in the context of two or more nucleotide or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms disclosed herein or by visual inspection.

10 The term "substantially identical" in regards to a nucleotide or polypeptide sequence means that a particular sequence varies from the sequence of a naturally occurring sequence by one or more deletions, substitutions, or additions, the net effect of which is to retain biological activity of a gene, gene product, or sequence of interest.

15 For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer program, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are selected. The sequence comparison algorithm then calculates the percent sequence identity for the designated test sequence(s) relative to the reference sequence, based on the selected program parameters.

Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman (1981) *Adv Appl Math* 2:482-489, by the homology alignment algorithm of Needleman & Wunsch (1970) *J Mol Biol* 48:443-453, by the search for similarity method of Pearson & Lipman (1988) *Proc Natl Acad Sci USA* 85:2444-2448, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, Wisconsin), or by visual inspection. See generally, Ausubel (ed.) (1995) Short Protocols in Molecular Biology, 3rd ed. Wiley, New York.

- 35 -

A preferred algorithm for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.* (1990) *J Mol Biol* 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold. These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when the cumulative alignment score falls off by the quantity X from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength W=11, an expectation E=10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix. See Henikoff & Henikoff (1992) *Proc Natl Acad Sci U S A* 89:10915-10919.

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences. See *e.g.*, Karlin & Altschul (1993) *Proc Natl Acad Sci U S A* 90:5873-5877. One measure of similarity provided by the BLAST algorithm

- 36 -

is the smallest sum probability ( $P(N)$ ), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

#### IV. Tumor Diagnosis, Treatment, and Imaging

The present invention further provides methods and compositions for x-ray guided drug delivery to a tumor in a subject. The term "drug" as used herein refers to any substance having biological or detectable activity. Thus, the term "drug" includes a pharmaceutical agent, a diagnostic agent, or a combination thereof. The term "drug" also includes any substance that is desirably delivered to a tumor.

Thus, in one embodiment of the invention, a composition is prepared, the composition comprising a targeting ligand as disclosed herein and a diagnostic agent. The composition can be used for the detection of a tumor in a subject by: (a) exposing a suspected tumor to ionizing radiation; (b) administering to the subject a targeting ligand of the invention, wherein the ligand comprises a detectable label; and (c) detecting the detectable label, whereby a tumor is diagnosed. Alternatively, a method for detecting a tumor can comprise: (a) exposing a suspected tumor to ionizing radiation; (b) biopsing a suspected tumor; (c) contacting a targeting ligand of the invention with the suspected tumor *in vitro*, wherein the ligand comprises a detectable label; and (d) detecting the detectable label, whereby a tumor is diagnosed.

A therapeutic composition of the present invention can comprise one or more targeting ligands and a therapeutic agent, such that the therapeutic agent can be selectively targeted to an irradiated tumor. The one or more targeting ligands can comprise ligands having diverse molecular features. For example, one or more targeting ligands can comprise both peptide and antibody targeting ligands.

Optionally, a therapeutic composition can additionally comprise a detectable label, preferably a label that can be detected *in vivo*. The biodistribution of the therapeutic composition so prepared can be monitored following administration to a subject.

- 5           Methods for preparation, labeling, and x-ray guided drug delivery using targeting ligands of the present invention are described further herein below. *See also* Examples 1 and 2.

#### IV.A. Therapeutic Agents

- 10           The novel targeting ligands disclosed here are used to target a therapeutic agent to an irradiated tumor. Representative therapeutic agents include but are not limited to a nucleic acid (*e.g.*, a therapeutic gene) and a small molecule. In a preferred embodiment of the invention, an inactive drug is administered, which is subsequently activated by irradiation (Hallahan *et al.*, 1995b). For example, therapeutic gene expression can be regulated by  
15           a radiation-inducible promoter (Hallahan *et al.*, 1995b).

- Therapeutic Genes. Angiogenesis and suppressed immune response play a central role in the pathogenesis of malignant disease and tumor growth, invasion, and metastasis. Thus, a preferred therapeutic gene encodes a polypeptide having an ability to induce an immune response  
20           and/or an anti-angiogenic response *in vivo*.

- The term "immune response" is meant to refer to any response to an antigen or antigenic determinant by the immune system of a vertebrate subject. Exemplary immune responses include humoral immune responses (*e.g.* production of antigen-specific antibodies) and cell-mediated immune  
25           responses (*e.g.* lymphocyte proliferation),

- Representative therapeutic proteins with immunostimulatory effects include but are not limited to cytokines (*e.g.*, IL2, IL4, IL7, IL12, interferons, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor alpha (TNF- $\alpha$ )), immunomodulatory cell surface proteins  
30           (*e.g.*, human leukocyte antigen (HLA proteins), co-stimulatory molecules, and tumor-associated antigens. *See* Kirk & Mule (2000) *Hum Gene Ther*

11:797-806; Mackensen *et al.* (1997) *Cytokine Growth Factor Rev* 8:119-128; Walther & Stein (1999) *Mol Biotechnol* 13:21-28; and references cited therein.

5 The term "angiogenesis" refers to the process by which new blood vessels are formed. The term "anti-angiogenic response" and "anti-angiogenic activity" as used herein, each refer to a biological process wherein the formation of new blood vessels is inhibited.

Representative proteins with anti-angiogenic activities that can be used in accordance with the present invention include: thrombospondin I  
10 (Kosfeld & Frazier, 1993; Tolsma *et al.*, 1993; Dameron *et al.*, 1994), metallospondin proteins (Carpizo & Iruela-Arispe, 2000), class I interferons (Albini *et al.*, 2000), IL12 (Voest *et al.*, 1995), protamine (Ingber *et al.*, 1990), angiostatin (O'Reilly *et al.*, 1994), laminin (Sakamoto *et al.*, 1991), endostatin (O'Reilly *et al.*, 1997), and a prolactin fragment (Clapp *et al.*, 1993). In  
15 addition, several anti-angiogenic peptides have been isolated from these proteins (Maione *et al.*, 1990; Eijan *et al.*, 1991; Woltering *et al.*, 1991).

A gene therapy construct used in accordance with the methods of the present invention can also encode a therapeutic gene that displays both immunostimulatory and anti-angiogenic activities, for example, IL12 (See  
20 Dias *et al.* (1998) *Int J Cancer* 75:151-157; and references cited herein below), interferon- $\alpha$  (O'Byrne *et al.*, 2000), and references cited therein), or a chemokine (Nomura & Hasegawa, 2000, and references cited therein). In addition, a gene therapy construct can encode a gene product with immunostimulatory activity *and* a gene product having anti-angiogenic  
25 activity. *See e.g.* Narvaiza *et al.* (2000) *J Immunol* 164:3112-3122.

Additional compositions useful for cancer therapy include but are not limited to genes encoding tumor suppressor gene products/antigens, antimetabolites, suicide gene products, and combinations thereof. *See* Kirk & Mule (2000) *Hum Gene Ther* 11:797-806; Mackensen *et al.* (1997)  
30 *Cytokine Growth Factor Rev* 8:119-128; Walther & Stein (1999) *Mol Biotechnol* 13:21-28; and references cited therein.

Therapeutic Compounds. In accordance with the methods of the present invention, a therapeutic agent can also comprise a cytotoxic agent, a chemotherapeutic agent, a radionuclide, or any other anti-tumor molecule. Studies using ligand/drug conjugates have demonstrated that a  
5 chemotherapeutic agent can be linked to a ligand to produce a conjugate that maintains the binding specificity of the ligand and the therapeutic function of the agent. For example, doxorubicin has been linked to antibodies or peptides and the ligand/doxorubicin conjugates display cytotoxic activity (Shih *et al.*, 1994; Lau *et al.*, 1995; Sivam *et al.*, 1995), PCT  
10 International Publication No. WO 98/10795). Similarly, other anthracyclines, including idarubicin and daunorubicin, have been chemically conjugated to antibodies, which have facilitated delivery of effective doses of the agents to tumors (Aboud-Pirak *et al.*, 1989; Rowland *et al.*, 1993). Other chemotherapeutic agents include cis-platinum (Schechter *et al.*, 1991),  
15 methotrexate (Shawler *et al.*, 1988; Fitzpatrick & Garnett, 1995) and mitomycin-C (Dillman *et al.*, 1989).

In another embodiment of the invention, a therapeutic agent comprises a radionuclide. Radionuclides can be effectively conjugated to antibodies (Hartmann *et al.*, 1994; Buchsbaum *et al.*, 1995), small molecule  
20 ligands (Wilbur, 1992; Fjalling *et al.*, 1996), and peptides (Boerman *et al.*, 2000; Krenning & de Jong, 2000; Kwekkeboom *et al.*, 2000; Virgolini *et al.*, 2001, and references cited therein), such that administration of the conjugated radionuclide promotes tumor regression. Representative therapeutic radionuclides and methods for preparing a radionuclide-labeled  
25 agent are described further herein below under the heading Scintigraphic Imaging. For therapeutic methods of the present invention, a preferred radionuclide comprises  $^{131}\text{I}$ .

Additional anti-tumor agents that can be conjugated to the targeting ligands disclosed herein and used in accordance with the therapeutic  
30 methods of the present invention include but are not limited to alkylating agents such as melphalan and chlorambucil (Smyth *et al.*, 1987; Aboud-Pirak *et al.*, 1989; Rowland *et al.*, 1993), vinca alkaloids such as vindesine

and vinblastine (Aboud-Pirak *et al.*, 1989; Starling *et al.*, 1992), antimetabolites such as 5-fluorouracil, 5-fluorouridine and derivatives thereof (Krauer *et al.*, 1992; Henn *et al.*, 1993).

#### IV.B. Preparation of a Therapeutic and/or Diagnostic Composition

5       The present invention also provides a method for preparing a composition for x-ray-guided drug delivery. The method comprises: (a) performing *in vivo* panning, whereby a ligand that binds a radiation-inducible tumor molecule is identified; and (b) conjugating the ligand to a drug, whereby a composition for x-ray-guided drug delivery is prepared. A drug  
10       can further comprise a drug carrier and can be formulated in any manner suitable for administration to a subject. In a preferred embodiment of the invention, the method employs a targeting ligand identified by *in vivo* panning comprising any one of SEQ ID NOs:1-13, 18, and 20.

Drug Carriers. The compositions of the present invention can further  
15       comprise a drug carrier to facilitate drug preparation and administration. Any suitable drug delivery vehicle or carrier can be used, including but not limited to a gene therapy vector (*e.g.*, a viral vector or a plasmid), a microcapsule, for example a microsphere or a nanosphere (Manome *et al.*, 1994; Hallahan, 2001a; Saltzman & Fung, 1997), a peptide (U.S. Patent Nos. 6,127,339 and  
20       5,574,172), a glycosaminoglycan (U.S. Patent No. 6,106,866), a fatty acid (U.S. Patent No. 5,994,392), a fatty emulsion (U.S. Patent No. 5,651,991), a lipid or lipid derivative (U.S. Patent No. 5,786,387), collagen (U.S. Patent No. 5,922,356), a polysaccharide or derivative thereof (U.S. Patent No. 5,688,931), a nanosuspension (U.S. Patent No. 5,858,410), a polymeric  
25       micelle or conjugate (Goldman *et al.*, 1997 and U.S. Patent Nos. 4,551,482, 5,714,166, 5,510,103, 5,490,840, and 5,855,900), and a polysome (U.S. Patent No. 5,922,545).

Conjugation of Targeting Ligands. Antibodies, peptides, or other  
ligands can be coupled to drugs or drug carriers using methods known in the  
30       art, including but not limited to carbodiimide conjugation, esterification, sodium periodate oxidation followed by reductive alkylation, and glutaraldehyde crosslinking. See Goldman *et al.* (1997) *Cancer Res*

57:1447-1451; Cheng (1996) *Hum Gene Ther* 7:275-282; Neri *et al.* (1997) *Nat Biotechnol* 15:1271-1275; Nabel (1997), *Current Protocols in Human Genetics*. John Wiley & Sons, New York, Vol. on CD-ROM; Park *et al.* (1997) *Adv Pharmacol* 40:399-435; Pasqualini *et al.* (1997) *Nat Biotechnol* 15:542-546; Bauminger & Wilchek (1980) *Methods Enzymol* 70:151-159; U.S. Patent No. 6,071,890; and European Patent No. 0 439 095.

In addition, a targeting peptide or antibody can be recombinantly expressed. For example, a nucleotide sequence encoding a targeting peptide or ligand can be cloned into adenovirus DNA encoding the H1 loop fiber, such that the targeting peptide or ligand is extracellularly presented. An adenovirus vector so prepared can be used for x-ray-guided delivery of a gene therapy construct as disclosed herein. A modified adenovirus vector encoding the RGD peptide was observed to transduce the endothelium in tumor blood vessels.

Formulation. A therapeutic composition, a diagnostic composition, or a combination thereof, of the present invention preferably comprises a pharmaceutical composition that includes a pharmaceutically acceptable carrier. Suitable formulations include aqueous and non-aqueous sterile injection solutions which can contain anti-oxidants, buffers, bacteriostats, bactericidal antibiotics and solutes which render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions which can include suspending agents and thickening agents. The formulations can be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and can be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of sterile liquid carrier, for example water for injections, immediately prior to use. Some preferred ingredients are SDS, for example in the range of 0.1 to 10 mg/ml, preferably about 2.0 mg/ml; and/or mannitol or another sugar, for example in the range of 10 to 100 mg/ml, preferably about 30 mg/ml; and/or phosphate-buffered saline (PBS). Any other agents conventional in the art having regard to the type of formulation in question can be used.

The therapeutic regimens and pharmaceutical compositions of the invention can be used with additional adjuvants or biological response modifiers including, but not limited to, the cytokines IFN- $\alpha$ , IFN- $\gamma$ , IL2, IL4, IL6, TNF, or other cytokine affecting immune cells.

5        IV.C. Administration

Suitable methods for administration of a therapeutic composition, a diagnostic composition, or combination thereof, of the present invention include but are not limited to intravascular, subcutaneous, or intratumoral administration. Preferably, intravascular administration is employed. For  
10 delivery of compositions to pulmonary pathways, compositions can be administered as an aerosol or coarse spray.

For therapeutic applications, a therapeutically effective amount of a composition of the invention is administered to a subject. A "therapeutically effective amount" is an amount of the therapeutic composition sufficient to  
15 produce a measurable biological tumor response (*e.g.*, an immunostimulatory, an anti-angiogenic response, a cytotoxic response, or tumor regression). Actual dosage levels of active ingredients in a therapeutic composition of the invention can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired  
20 therapeutic response for a particular subject. The selected dosage level will depend upon a variety of factors including the activity of the therapeutic composition, formulation, the route of administration, combination with other drugs or treatments, tumor size and longevity, and the physical condition and prior medical history of the subject being treated. Preferably, a minimal  
25 dose is administered, and dose is escalated in the absence of dose-limiting toxicity. Determination and adjustment of a therapeutically effective dose, as well as evaluation of when and how to make such adjustments, are known to those of ordinary skill in the art of medicine.

For diagnostic applications, a detectable amount of a composition of  
30 the invention is administered to a subject. A "detectable amount", as used herein to refer to a diagnostic composition, refers to a dose of such a

composition that the presence of the composition can be determined *in vivo* or *in vitro*. A detectable amount will vary according to a variety of factors, including but not limited to chemical features of the drug being labeled, the detectable label, labeling methods, the method of imaging and parameters  
5 related thereto, metabolism of the labeled drug in the subject, the stability of the label (e.g. the half-life of a radionuclide label), the time elapsed following administration of the drug and/or labeled antibody prior to imaging, the route of drug administration, the physical condition and prior medical history of the subject, and the size and longevity of the tumor or suspected tumor. Thus, a  
10 detectable amount can vary and is preferably tailored to a particular application. After study of the present disclosure, and in particular the Examples, it is within the skill of one in the art to determine such a detectable amount.

#### IV.D. Radiation Treatment

15 The disclosed targeting ligands are useful for x-ray guided drug delivery. Targeted drug delivery to a tumor in a subject can be performed by irradiating the tumor prior to, concurrent with, or subsequent to administration of a composition of the present invention. In accordance with the *in vivo* panning methods for discovery of the targeting ligands, the tumor  
20 is preferably irradiated 0 hours to about 24 hours before administration of the composition, and more preferably about 4 hours to about 24 hours before administration of the composition.

Low doses of radiation can be used for selective targeting using the peptide ligands disclosed herein. Preferably, the dose of radiation  
25 comprises up to about 2 Gy ionizing radiation. Higher radiation doses can also be used, especially in the case of local radiation treatment as described herein below.

Radiation can be localized to a tumor using conformal irradiation, brachytherapy, or stereotactic irradiation. The threshold dose for inductive  
30 changes can thereby be exceeded in the target tissue but avoided in surrounding normal tissues. In this case, dose of at least about 2 Gy ionizing radiation can be used, and more preferably about 10 Gy to about 20

- 44 -

Gy ionizing radiation. For treatment of a subject having two or more tumors, local irradiation enables differential drug administration and/or dose at each of the two or more tumors. Alternatively, whole body irradiation can be used, as permitted by the low doses of radiation required for targeting of ligands disclosed herein. Radiotherapy methods suitable for use in the practice of this invention can be found in Leibel & Phillips (1998) Textbook of Radiation Oncology, Saunders, Philadelphia, among other sources.

#### IV.E. Monitoring Distribution In Vivo

In a preferred embodiment of the invention, a diagnostic and/or therapeutic composition for x-ray-guided drug delivery comprises a label that can be detected *in vivo*. The term "*in vivo*", as used herein to describe imaging or detection methods, refer to generally non-invasive methods such as scintigraphic methods, magnetic resonance imaging, ultrasound, or fluorescence, each described briefly herein below. The term "non-invasive methods" does not exclude methods employing administration of a contrast agent to facilitate *in vivo* imaging.

The label can be conjugated or otherwise associated with a targeting ligand (*e.g.*, any one of SEQ ID NOs:1-13, 18, 20), a therapeutic, a diagnostic agent, a drug carrier, or combinations thereof. Following administration of the labeled composition to a subject, and after a time sufficient for binding, the biodistribution of the composition can be visualized. The term "time sufficient for binding" refers to a temporal duration that permits binding of the labeled agent to a radiation-induced target molecule.

Scintigraphic Imaging. Scintigraphic imaging methods include SPECT (Single Photon Emission Computed Tomography), PET (Positron Emission Tomography), gamma camera imaging, and rectilinear scanning. A gamma camera and a rectilinear scanner each represent instruments that detect radioactivity in a single plane. Most SPECT systems are based on the use of one or more gamma cameras that are rotated about the subject of analysis, and thus integrate radioactivity in more than one dimension. PET systems comprise an array of detectors in a ring that also detect radioactivity in multiple dimensions.

A representative method for SPECT imaging is presented in Example 2. Other imaging instruments suitable for practicing the method of the present invention, and instruction for using the same, are readily available from commercial sources. Both PET and SPECT systems are offered by  
5 ADAC of Milpitas, California and Siemens of Hoffman Estates, Illinois. Related devices for scintigraphic imaging can also be used, such as a radio-imaging device that includes a plurality of sensors with collimating structures having a common source focus.

When scintigraphic imaging is employed, the detectable label  
10 preferably comprises a radionuclide label, more preferably a radionuclide label selected from the group consisting of <sup>18</sup>F, <sup>64</sup>Cu, <sup>65</sup>Cu, <sup>67</sup>Ga, <sup>68</sup>Ga, <sup>77</sup>Br, <sup>80m</sup>Br, <sup>95</sup>Ru, <sup>97</sup>Ru, <sup>103</sup>Ru, <sup>105</sup>Ru, <sup>99m</sup>Tc, <sup>107</sup>Hg, <sup>203</sup>Hg, <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, <sup>126</sup>I, <sup>131</sup>I, <sup>133</sup>I, <sup>111</sup>In, <sup>113</sup>In, <sup>99m</sup>Rh, <sup>105</sup>Rh, <sup>101</sup>Rh, <sup>186</sup>Rh, <sup>188</sup>Rh, <sup>121</sup>Te, <sup>122m</sup>Te, <sup>125m</sup>Te, <sup>165</sup>Tl, <sup>167</sup>Tl, <sup>168</sup>Tl, and nitride or oxide forms derived there from. In a preferred embodiment of the invention, the radionuclide label comprises <sup>131</sup>I or <sup>99m</sup>Tc.

Methods for radionuclide-labeling of a molecule so as to be used in  
20 accordance with the disclosed methods are known in the art. For example, a targeting molecule can be derivatized so that a radioisotope can be bound directly to it (Yoo *et al.*, 1997). Alternatively, a linker can be added that to enable conjugation. Representative linkers include diethylenetriamine pentaacetate (DTPA)-isothiocyanate, succinimidyl 6-hydrazinium nicotinate  
25 hydrochloride (SHNH), and hexamethylpropylene amine oxime (HMPAO) (Chattopadhyay *et al.*, 2001; Sagiuchi *et al.*, 2001; Dewanjee *et al.*, 1994; U.S. Patent No. 6,024,938). Additional methods can be found in U.S. Patent No. 6,080,384; Hnatowich *et al.* (1996) *J Pharmacol Exp Ther* 276:326-334; and Tavittian *et al.* (1998) *Nat Med* 4:467-471.

30 When the labeling moiety is a radionuclide, stabilizers to prevent or minimize radiolytic damage, such as ascorbic acid, gentisic acid, or other

appropriate antioxidants, can be added to the composition comprising the labeled targeting molecule.

Magnetic Resonance Imaging (MRI). Magnetic resonance image-based techniques create images based on the relative relaxation rates of water protons in unique chemical environments. As used herein, the term “magnetic resonance imaging” refers to magnetic source techniques including convention magnetic resonance imaging, magnetization transfer imaging (MTI), proton magnetic resonance spectroscopy (MRS), diffusion-weighted imaging (DWI) and functional MR imaging (fMRI). See Rovaris *et al.* (2001) *J Neurol Sci* 186 Suppl 1:S3-9; Pomper & Port (2000) *Magn Reson Imaging Clin N Am* 8:691-713; and references cited therein.

Contrast agents for magnetic source imaging include but are not limited to paramagnetic or superparamagnetic ions, iron oxide particles (Weissleder *et al.*, 1992; Shen *et al.*, 1993), and water-soluble contrast agents. Paramagnetic and superparamagnetic ions can be selected from the group of metals including iron, copper, manganese, chromium, erbium, europium, dysprosium, holmium and gadolinium. Preferred metals are iron, manganese and gadolinium; most preferred is gadolinium.

Those skilled in the art of diagnostic labeling recognize that metal ions can be bound by chelating moieties, which in turn can be conjugated to a therapeutic agent in accordance with the methods of the present invention. For example, gadolinium ions are chelated by diethylenetriaminepentaacetic acid (DTPA). Lanthanide ions are chelated by tetraazacyclododecane compounds. See U.S. Patent Nos. 5,738,837 and 5,707,605. Alternatively, a contrast agent can be carried in a liposome (Schwendener, 1992).

Images derived using a magnetic source can be acquired using, for example, a superconducting quantum interference device magnetometer (SQUID, available with instruction from Quantum Design of San Diego, California). See U.S. Patent No. 5,738,837.

Ultrasound. Ultrasound imaging can be used to obtain quantitative and structural information of a target tissue, including a tumor. Administration of a contrast agent, such as gas microbubbles, can enhance

- visualization of the target tissue during an ultrasound examination. Preferably, the contrast agent can be selectively targeted to the target tissue of interest, for example by using a peptide for x-ray guided drug delivery as disclosed herein. Representative agents for providing microbubbles *in vivo*
- 5 include but are not limited to gas-filled lipophilic or lipid-based bubbles (*e.g.*, U.S. Patent Nos. 6,245,318, 6,231,834, 6,221,018, and 5,088,499). In addition, gas or liquid can be entrapped in porous inorganic particles that facilitate microbubble release upon delivery to a subject (U.S. Patent Nos. 6,254,852 and 5,147,631).
- 10 Gases, liquids, and combinations thereof suitable for use with the invention include air; nitrogen; oxygen; is carbon dioxide; hydrogen; nitrous oxide; an inert gas such as helium, argon, xenon or krypton; a sulphur fluoride such as sulphur hexafluoride, disulphur decafluoride or trifluoromethylsulphur pentafluoride; selenium hexafluoride; an optionally
- 15 halogenated silane such as tetramethylsilane; a low molecular weight hydrocarbon (*e.g.* containing up to 7 carbon atoms), for example an alkane such as methane, ethane, a propane, a butane or a pentane, a cycloalkane such as cyclobutane or cyclopentane, an alkene such as propene or a butene, or an alkyne such as acetylene; an ether; a ketone; an ester; a
- 20 halogenated low molecular weight hydrocarbon (*e.g.* containing up to 7 carbon atoms); or a mixture of any of the foregoing. Halogenated hydrocarbon gases can show extended longevity, and thus are preferred for some applications. Representative gases of this group include decafluorobutane, octafluorocyclobutane, decafluoroisobutane,
- 25 octafluoropropane, octafluorocyclopropane, dodecafluoropentane, decafluorocyclopentane, decafluoroisopentane, perfluoropexane, perfluorocyclohexane, perfluoroisohexane, sulfur hexafluoride, and perfluorooctanes, perfluorononanes; perfluorodecanes, optionally brominated.
- 30 Attachment of targeting ligands to lipophilic bubbles can be accomplished via chemical crosslinking agents in accordance with standard protein-polymer or protein-lipid attachment methods (*e.g.*, via carbodiimide

(EDC) or thiopropionate (SPDP)). To improve targeting efficiency, large gas-filled bubbles can be coupled to a targeting ligand using a flexible spacer arm, such as a branched or linear synthetic polymer (U.S. Patent No. 6,245,318). A targeting ligand can be attached to the porous inorganic particles by coating, adsorbing, layering, or reacting the outside surface of the particle with the targeting ligand (U.S. Patent No. 6,254,852).

A description of ultrasound equipment and technical methods for acquiring an ultrasound dataset can be found in Coatney (2001) *Ilar J* 42:233-247, Lees (2001) *Semin Ultrasound CT MR* 22:85-105, and references cited therein.

Fluorescent Imaging. Non-invasive imaging methods can also comprise detection of a fluorescent label. A drug comprising a lipophilic component (therapeutic agent, diagnostic agent, vector, or drug carrier) can be labeled with any one of a variety of lipophilic dyes that are suitable for *in vivo* imaging. See e.g. Fraser (1996) *Methods Cell Biol* 51:147-160; Ragnarson *et al.* (1992) *Histochemistry* 97:329-333; and Heredia *et al.* (1991) *J Neurosci Methods* 36:17-25. Representative labels include but are not limited to carbocyanine and aminostyryl dyes, preferably long chain dialkyl carbocyanines (e.g., Dil, DiO, and DiD available from Molecular Probes Inc. of Eugene, Oregon) and dialkylaminostyryl dyes. Lipophilic fluorescent labels can be incorporated using methods known to one of skill in the art. For example VYBRANT™ cell labeling solutions are effective for labeling of cultured cells of other lipophilic components (Molecular Probes Inc. of Eugene, Oregon). Preparation of liposomes comprising a targeting ligand and a Dil detectable label are described in Example 1.

A fluorescent label can also comprise sulfonated cyanine dyes, including Cy5.5 and Cy5 (available from Amersham of Arlington Heights, IL), IRD41 and IRD700 (available from Li-Cor, Inc. of Lincoln, Nebraska), NIR-1 (available from Dejindo of Kumamoto, Japan), and LaJolla Blue (available from Diatron of Miami, Florida). See also Licha *et al.* (2000) *Photochem*

*Photobiol* 72:392-398; Weissleder *et al.* (1999) *Nat Biotechnol* 17:375-378; and Vinogradov *et al.* (1996) *Biophys J* 70:1609-1617

In addition, a fluorescent label can comprise an organic chelate derived from lanthanide ions, for example fluorescent chelates of terbium and europium (U.S. Patent No. 5,928,627). Such labels can be conjugated  
5 or covalently linked to a drug as disclosed therein.

For *in vivo* detection of a fluorescent label, an image is created using emission and absorbance spectra that are appropriate for the particular label used. The image can be visualized, for example, by diffuse optical  
10 spectroscopy. Additional methods and imaging systems are described in U.S. Patent Nos. 5,865,754; 6,083,486; and 6,246,901, among other places.

#### IV.F. In Vitro Detection

The present invention further provides methods for diagnosing a tumor, wherein a tumor sample or biopsy is evaluated *in vitro*. In this case, a  
15 targeting ligand of the invention comprises a detectable label such as a fluorescent, epitope, or radioactive label, each described briefly herein below.

Fluorescence. Any detectable fluorescent dye can be used, including but not limited to FITC (fluorescein isothiocyanate), FLUOR X™, ALEXA  
20 FLUOR® , OREGON GREEN®, TMR (tetramethylrhodamine), ROX (X-rhodamine), TEXAS RED®, BODIPY® 630/650, and Cy5 (available from Amersham Pharmacia Biotech of Piscataway, New Jersey or from Molecular Probes Inc. of Eugene, Oregon).

A fluorescent label can be detected directly using emission and  
25 absorbance spectra that are appropriate for the particular label used. Common research equipment has been developed for *in vitro* detection of fluorescence, including instruments available from GSI Lumonics (Watertown, Massachusetts, United States of America) and Genetic Microsystems Inc. (Woburn, Massachusetts, United States of America).  
30 Most of the commercial systems use some form of scanning technology with photomultiplier tube detection. Criteria for consideration when analyzing

fluorescent samples are summarized by Alexay *et al.* (1996) *The PCT International Society of Optical Engineering* 2705/63.

Detection of an Epitope. If an epitope label has been used, a protein or compound that binds the epitope can be used to detect the epitope. A  
5 representative epitope label is biotin, which can be detected by binding of an avidin-conjugated fluorophore, for example avidin-FITC, as described in Example 7. Alternatively, the label can be detected by binding of an avidin-horseradish peroxidase (HRP) streptavidin conjugate, followed by colorimetric detection of an HRP enzymatic product. The production of a  
10 colorimetric or luminescent product/conjugate is measurable using a spectrophotometer or luminometer, respectively.

Autoradiographic Detection. In the case of a radioactive label (*e.g.*,  $^{131}\text{I}$  or  $^{99\text{m}}\text{Tc}$ ) detection can be accomplished by conventional autoradiography or by using a phosphorimager as is known to one of skill in  
15 the art. A preferred autoradiographic method employs photostimulable luminescence imaging plates (Fuji Medical Systems of Stamford, Connecticut). Briefly, photostimulable luminescence is the quantity of light emitted from irradiated phosphorous plates following stimulation with a laser during scanning. The luminescent response of the plates is linearly  
20 proportional to the activity (Amemiya *et al.*, 1988; Hallahan *et al.*, 2001b).

#### V. Identification of a Radiation-Induced Target Molecule

Targeting ligands obtained using the methods disclosed herein can be used to identify and/or isolate a target molecule that is recognized by the targeting ligand. Representative methods include affinity chromatography,  
25 biotin trapping, and two-hybrid analysis, each described briefly herein below.

Affinity Chromatography. A representative method for identification of a radiation-induced target molecule is affinity chromatography. For example, a targeting ligand as disclosed herein can be linked to a solid support such as a chromatography matrix. A sample derived from an irradiated tumor is  
30 prepared according to known methods in the art, and such sample is provided to the column to permit binding of a target molecule. The target molecule, which forms a complex with the targeting ligand, is eluted from the

column and collected in a substantially isolated form. The substantially isolated target molecule is then characterized using standard methods in the art. See Deutscher (1990) Guide to Protein Purification. Academic Press, San Diego.

5        Biotin Trapping. A related method employs a biotin-labeled targeting ligand such that a complex comprising the biotin-labeled targeting ligand bound to a target molecule can be purified based on affinity to avidin, which is provided on a support (e.g., beads, a column). A targeting ligand comprising a biotin label can be prepared by any one of several methods,  
10 including binding of biotin maleimide [3-(N-maleimidylpropionyl)biocytin] to cysteine residues of a peptide ligand (Tang & Casey, 1999), binding of biotin to a biotin acceptor domain, for example that described in *K. pneumoniae* oxaloacetate decarboxylase, in the presence of biotin ligase (Julien *et al.*, 2000), attachment of biotin amine to reduced sulfhydryl groups (U.S. Patent  
15 No. 5,168,037), and chemical introduction of a biotin group into a nucleic acid ligand, (Carninci *et al.*, 1996). Preferably, a biotin-labeled targeting ligand and the unlabeled same target ligand show substantially similar binding to a target molecule.

Two-Hybrid Analysis. As another example, targeting ligands can be  
20 used to identify a target molecule using a two-hybrid assay, for example a yeast two-hybrid or mammalian two-hybrid assay. In one embodiment of the method, a targeting ligand is fused to a DNA binding domain from a transcription factor (this fusion protein is called the "bait"). Representative DNA-binding domains include those derived from GAL4, LEXA, and mutant  
25 forms thereof. One or more candidate target molecules is fused to a transactivation domain of a transcription factor (this fusion protein is called the "prey"). Representative transactivation domains include those derived from *E. coli* B42, GAL4 activation domain II, herpes simplex virus VP16, and mutant forms thereof. The fusion proteins can also include a nuclear  
30 localization signal.

The transactivation domain should be complementary to the DNA-binding domain, meaning that it should interact with the DNA-binding domain

so as to activate transcription of a reporter gene comprising a binding site for the DNA-binding domain. Representative reporter genes enable genetic selection for prototrophy (*e.g.* LEU2, HIS3, or LYS2 reporters) or by screening with chromogenic substrates (*lacZ* reporter).

5 The fusion proteins can be expressed from a same vector or different vectors. The reporter gene can be expressed from a same vector as either fusion protein (or both proteins), or from a different vector. The bait, prey, and reporter genes are co-transfected into an assay cell, for example a microbial cell (*e.g.*, a bacterial or yeast cell), an invertebrate cell (*e.g.*, an insect cell), or a vertebrate cell (*e.g.*, a mammalian cell, including a human cell). Cells that display activity of the encoded reporter are indicative of a binding interaction between the peptide and the candidate target molecule. The protein encoded by such a clone is identified using standard protocols known to one of skill in the art.

15 Additional methods for yeast two-hybrid analysis can be found in  
Brent & Finley (1997) *Annu Rev Genet* 31:663-704; Allen *et al.* (1995)  
*Trends Biochem Sci* 20:511-516; Lecrenier *et al.* (1998) *Bioessays* 20:1-5;  
Yang *et al.* (1995) *Nucleic Acids Res* 23:1152-1156; Bendixen *et al.* (1994)  
*Nucleic Acids Res* 22:1778-1779; Fuller *et al.* (1998) *Biotechniques* 25:85-  
20 88, 90-82; Cohen *et al.* (1998) *Proc Natl Acad Sci U S A* 95:14272-14277;  
Kolonin & Finley (1998) *Proc Natl Acad Sci U S A* 95:14266-14271;  
Vasavada *et al.* (1991) *Proc Natl Acad Sci U S A* 88:10686-10690; Rehrauer  
*et al.* (1996) *J Biol Chem* 271:23865-23873; and Fields & Song (1989)  
*Nature* 340:245-246.

25 Examples

The following Examples have been included to illustrate modes of the invention. Certain aspects of the following Examples are described in terms of techniques and procedures found or contemplated by the present co-inventors to work well in the practice of the invention. These Examples illustrate standard laboratory practices of the co-inventors. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following Examples are intended to be exemplary only

and that numerous changes, modifications, and alterations can be employed without departing from the scope of the invention.

#### Example 1

##### X-Ray Guided Delivery of Fibrinogen-Conjugated

##### 5                   Liposomes and Microspheres

Preparation of Radiolabeled Microspheres. Albumin microspheres (Martodam *et al.*, 1979) were resuspended using 10 ml of sterile normal saline (0.9% NaCl). One-half milliliter of the reconstituted microsphere was added to a 1.5ml conical polypropylene tube previously coated with lodgen (Pierce of Rockford, Illinois). To this, 11.3 mCi (418 megabecquerel (MBq)) of <sup>131</sup>I (DuPont Pharmaceuticals of Wilmington, Delaware) was added in approximately 11 µl of saline and allowed to incubate at room temperature for 30 minutes. Following incubation, the microspheres were transferred to a 15 ml sterile centrifuge tube, diluted to 10 ml with normal saline and centrifuged at 1,500g for seven minutes. The supernatant was removed and discarded. The microspheres were washed one additional time with 10 ml of normal saline and centrifuged. The microspheres were suspended in 2 ml of normal saline for injection. Final yield was 4.8 mCi (177.6 MBq) of radioiodinated microspheres in 2 ml saline. Radiochemical yield was 42.4%.

20           Preparation of Fibrinogen-Conjugated Liposomes. The lipophilic SH reactive reagent with a long spacing arm was synthesized from maleimide-PEG 2000-NSH ester (Prochem Chemicals of High Point, North Carolina), dioleoylphosphatidylethanolamine (DOPE, available from AVANTI® Polar Lipids, Inc. of Alabaster, Alabama) and triethylamine in chloroform (1:1:1.5).  
25   Resulting maleimide-PEG 2000-DOPE was purified by flash column. Under stirring, to a solution of fibrinogen (2mg/ml) in 0.01M HEPES 0.15 NaCl buffer pH7.9, containing 10mM EDTA and 0.08% NaN<sub>3</sub> was added in 5-fold excess of freshly prepared Traut's reagent (2-iminothiolane hydrochloride) in the same buffer. The reaction was allowed to proceed for 30 minutes at 0°C.  
30           SH-fibrinogen was purified using a PD-10 desalting and buffer exchange column (Amersham Pharmacia Biotech of Piscataway, New

- 54 -

Jersey). PEG 2000-PE, cholesterol, Dipalmitoyl phosphocholine (AVANTI® Polar Lipids, Inc. of Alabaster, Alabama), Dil (lipid fluorescent marker available from Molecular Probes of Eugene, Oregon), and maleimide-PEG-2000-DOPE were dissolved in chloroform and mixed at a molar ratio of 10:43:43:2:2, respectively, in a round bottom flask. The organic solvent was removed by evaporation followed by desiccation under vacuum for 2 hours. Liposomes were prepared by hydrating the dried lipid film in PBS at a lipid concentration of 10mM. The suspension was then sonicated 3 x 5 minutes, or until the solution appeared clear, to form unilamellar liposomes of 100 nM in diameter. To conjugate thiolated fibrinogen to maleimide containing liposomes, prepared vesicles and thiolated protein were mixed in 10mM Hepes, 0.15M NaCl and EDTA pH 6.5. The final concentrations for proteins and liposomes were 0.25 g/L and 2.5mM, respectively. The peptide/liposome mixture was incubated for 18 hours at room temperature. Vesicles were then separated from unconjugated peptide using a sepharose 4B-CL filtration column (Amersham Pharmacia Biotech of Piscataway, New Jersey).

Liposomes were fluorescently labeled with Dil fluorescent marker (Molecular Probes, Inc. of Eugene, Oregon) according to the manufacturer's instructions. Labeled liposomes were administered by tail vein injection to tumor bearing mice. Tumors were treated with 4 Gy either prior to administration or after administration of fibrinogen-liposome conjugates. Tumors were fixed and sectioned at 24 hours following irradiation. Fluorescence was imaged by ultraviolet microscopy (100X).

Image Analysis. Tumor bearing mice were imaged at one hour and 24 hours post-administration of radiolabeled proteins. Planar pinhole gamma camera imaging was performed on a single-head gamma camera (HELIX® model from General Electric Medical Systems of Milwaukee, Wisconsin) using a cone-shaped pinhole collimator with a 4-mm diameter Tungsten aperture. Pinhole collimation offers the advantage of improved photon detection efficiency (sensitivity) and spatial resolution when compared with conventional, parallel multi-hole collimators. Pinhole planar

imaging with a small source-aperture separation can provide high-resolution images combined with large magnification. Each scan consisted of a 180-second acquisition (256 x 256 acquisition matrix) with a 10% energy window centered on 364 keV. The source-aperture separation was 6.0 cm.

5 Prior to imaging analysis in animals, a uniform  $^{131}\text{I}$  disk source was imaged in order to measure the angular dependence of the pinhole collimator – gamma camera system detection efficiency with distance from the center of the pinhole. Angular sensitivity, normalized to 1.0 at the center of the pinhole, was then used to scale the mouse data in order to correct  
10 image counts for this geometrical effect. A calibration source of known  $^{131}\text{I}$  activity was also scanned at a 6.0cm source-aperture separation distance in order to measure system sensitivity along the center of the pinhole.

Peptide biodistribution data was assessed using two measures: (1) tumor-to-background ratio (T/B) of observed activity; and (2) tumor uptake  
15 activity in  $\mu\text{Ci}$ . Both types of data were obtained using region-of-interest (ROI) analysis. For both measurements an 11 x 11 ROI was used to determine mean counts within the tumor ( $\sigma_T$ ) and at five different locations within the mouse background ( $\sigma_B$ ). These readings were scaled to account for geometric sensitivity and the ratio of tumor uptake to total animal uptake  
20 (R) was computed according to the relation,

$$R = \frac{\sigma_T}{(\sigma_T + \sigma_B)}.$$

Activity uptake in the tumor was then approximated by the product of the amount of activity administered into the animal multiplied by the value obtained for R above. Tumor-background ratios were determined according  
25 to the general expression:

$$\left(\frac{T}{B}\right) = \frac{\sigma_T}{\sigma_B}.$$

#### Fibrinogen Coated Microsphere Localize to Irradiated Tumors.

Fibrinogen-coated microspheres were radiolabeled with  $^{131}\text{I}$  and administered by tail vein injection into tumor bearing mice, and tumors were

irradiated with 6 Gy. The specificity of fibrinogen-coated albumin was determined by measuring the intensity of gamma detection within regions of interest (ROI) and well counts of tumor and other tissues. In animals receiving localized radiation at the tumor site, 90% of the measured  
5 radioactivity was localized to the tumor, and 10% of the radioactivity was diffusely distributed throughout the entire animal model. In untreated controls, 10% of radioactive counts were localized to the tumor ( $p < 0.001$ ).

During optimization studies, tumors were irradiated immediately before or immediately after tail vein injection. Both schedules were effective  
10 in achieving  $^{131}\text{I}$ -fibrinogen-coated microsphere binding. However, tumor irradiation subsequent to microsphere administration achieved increased targeting specificity when compared to tumors irradiated prior to microsphere administration. Microspheres lacking the fibrinogen ligand did not bind irradiated tumors.

15 To quantify a level of preferential binding of fibrinogen coated microspheres in irradiated tumors, data were normalized based on background levels of radiation. Fibrinogen-coated microspheres were 100-fold more abundant in irradiated tumors compared to non-tumor control tissues. By contrast, microspheres lacking the fibrinogen ligand were  
20 detected at similar levels in tumor and non-tumor control tissues.

To determine whether fibrinogen-conjugated microspheres bind irradiated non-tumor control tissues, the entire hind quarters of mice bearing hind limb tumors were irradiated, and radiolabeled fibrinogen-coated microspheres were administered immediately after irradiation. Well counts  
25 of all tissues were performed at 24 hours after irradiation. 90% of radioactive counts were detected in the tumor. By contrast, 2% of radioactive counts were detected in irradiated non-tumor control tissue, demonstrating selective targeting of fibrinogen-coated microspheres to irradiated tumors.

30 Fibrinogen-Liposome Conjugates Localize to Irradiated Tumors.

Fibrinogen-conjugated, fluorescently labeled liposomes were administered by tail vein into mice bearing tumors on both hind limbs. The

- 57 -

right tumor was treated with radiation and the left tumor served as the untreated control. Untreated control tumors showed no fibrinogen-liposome conjugate binding whereas tumors irradiated immediately before or immediately after tail vein injection showed fibrinogen adhesion in blood vessels. The fluorescent marker was observed within the vascular lumen of tumor microvasculature.

Studies using radiolabeled fibrinogen-conjugated liposomes gave similar results. When liposomes were administered after tumor irradiation, 89% of fibrinogen-coated liposomes localized to tumors. When liposomes were administered immediately prior to tumor irradiation, 69% of liposomes showed tumor localization. By contrast, in untreated controls, a background level of 9% of fibrinogen-coated liposomes localized to the tumor.

### Example 2

#### Clinical Trials of X-Ray-Guided Delivery Using a Peptide Ligand

##### Ligand Preparation and Administration.

Biapcitide (ACUTECT® available from Diatide, Inc. of Londonderry, New Hampshire) is a synthetic peptide that binds to GP-IIb/IIIa receptors on activated platelets (Hawiger *et al.*, 1989; Hawiger & Timmons, 1992). Biapcitide was labeled with <sup>99m</sup>Tc in accordance with a protocol provided by Diatide Inc.

Reconstituted <sup>99m</sup>Tc-labeled biapcitide was administered to patients at a dose of 100 mcg of biapcitide radiolabeled with 10 mCi of <sup>99m</sup>Tc. Patients received <sup>99m</sup>Tc-labeled biapcitide intravenously immediately prior to irradiation. Patients were then treated with 10 Gy or more. Patients underwent gamma camera imaging prior to irradiation and 24 hours following irradiation. Following planar image acquisition, those patients showing uptake in irradiated tumors underwent tomographic imaging using SPECT and repeat imaging at 24 hours. Patients showing no uptake on planer images during this 24-hour time frame had no further imaging. Each patient had an internal control, which consisted of a baseline scan immediately following administration of <sup>99m</sup>Tc-labeled biapcitide.

Patients were treated with X-irradiation ranging from 4 to 18 MV photon using external beam linear accelerator at Vanderbilt University. Appropriate blocks, wedges and bolus to deliver adequate dose to the planned target volume was utilized. The site of irradiation, treatment intent and normal tissue considerations determined the radiation dosage and volume. When stereotactic radiosurgery was used, the dose was prescribed to the tumor periphery.

Image Analysis. Image acquisition consisted of both planar and single photon emission computed tomography (SPECT) studies. Planar studies were performed on a dual-head gamma camera (Millenium VG – Variable Geometry model available from General Electric Medical Systems of Milwaukee, Wisconsin) equipped with low energy high-resolution (LEUR) collimators. This type of collimator represents a compromise between sensitivity (photon counting efficiency) and image resolution. Planar nuclear medicine images were acquired with a 256 x 256 acquisition matrix (pixel size approximately 0.178 cm/pixel) for 10 minutes. In order to maximize collimator-gamma camera system sensitivity the source-to-detector surface distance was minimized to the extent that patient geometry allows. The spatial distribution of fibrinogen within the planar image was measured using region-of-interest (ROI) analysis. Two different size ROI's (5 x 5 pixel, and 15 x 15 pixel) was used in both the tumor and surrounding organs and tissues in the patient. The rationale for using ROIs with different dimensions is to be able to quantify image counts while at the same time isolating any possible influence of ROI size on the results. Tumor-to-background ratios were computed as the ratio of average counts in the tumor region divided by average counts in surrounding organs and tissues, each corrected for background. Background counts was determined based on ROI analysis of a separate planar acquisition performed in the absence of a radioactive source.

Three-dimensional nuclear medicine SPECT examinations were performed using the same dual-head gamma camera system. Each SPECT study comprised a 360 scan acquired with a step-and-shoot approach

- 59 -

utilizing the following acquisition parameters: three increments between views, a 256 x 256 x 64 acquisition matrix, LEUR collimation and 60 seconds per view. Images were reconstructed using analytical filtered back-projection and statistical maximum likelihood techniques with photon  
5 attenuation correction and post-reconstruction deconvolution filtering for approximate detector response compensation. In this case, correction for background consisted of subtracting counts acquired in a single 60-second planar view from all views of the SPECT projection data prior to image reconstruction. SPECT tumor-to-background ratios were computed using  
10 quantitative ROI techniques identical to the planar studies.

Results. Administration of a  $^{99m}\text{Tc}$ -labeled biapticide, an RGD peptide mimetic, immediately prior to radiation resulted in tumor binding in 4 of 4 patients (Hallahan *et al.*, 2001a). Two patients among this group had second neoplasms that were not treated with radiation, and binding of  $^{99m}\text{Tc}$ -  
15 labeled biapticide was not observed in the untreated tumor. Administration of the  $^{99m}\text{Tc}$ -labeled biapticide within one hour following radiation also failed to show localization of the targeting molecule to the tumor (Hallahan *et al.*, 2001a).

### Example 3

#### 20 Response of Tumor Blood Vessels to Ionizing Radiation

To determine the response of tumor blood vessels to ionizing radiation, a tumor vascular window and Doppler sonography were used to measure the change in tumor blood vessels (Donnelly *et al.*, 2001; Geng *et al.*, 2001). Tumors implanted into the window model developed blood  
25 vessels within 1 week. Tumors were then treated with radiation and the response of blood vessels was imaged by use of light microscopy. Radiation doses in the range of 2-3 Gy increased the vascularity within tumors. In contrast, larger doses of radiation such as 6 Gy reduced tumor vascularity.

30 Established tumors were studied to determine whether there is a dose-dependent change in blood flow following irradiation. Tumors in the hind limb were grown to approximately 1 cm in diameter. Blood flow within

- 60 -

tumors was measured by use of power Doppler (Donnelly *et al.*, 2001). Tumors were treated with 3 Gy or 6 Gy ionizing radiation, and changes in tumor blood flow were measured using power Doppler sonography. A radiation dose of 3 Gy achieved an increase in tumor blood flow. In contrast, radiation doses of 6 Gy or higher markedly reduced tumor blood flow.

#### Example 4

##### Preparation of a Recombinant Peptide Library in Phage

A population of DNA fragments encoding recombinant peptide sequences was cloned into the T7 SELECT™ vector (Novagen of Madison, Wisconsin). Cloning at the EcoR I restriction enzyme recognition site places the recombinant peptide in-frame with the 10B protein such that the peptide is displayed on the capsid protein. The resulting reading frame requires an AAT initial codon followed by a TCX codon.

The molar ratio between insert and vector was 1:1. Size-fractionated cDNA inserts were prepared by gel filtration on sepharose 4B and ranged from 27 base pairs to 33 base pairs. cDNAs were ligated by use of the DNA ligation kit (Novagen of Madison, Wisconsin). Recombinant T7 DNA was packaged according to the manufacturer's instructions and amplified prior to biopanning in animal tumor models. The diversity of the library was  $10^7$ .

#### Example 5

##### In vivo Panning for Peptide Ligands to Radiation-Induced Molecules

GL261 murine glioma cells and Lewis lung carcinoma cells were implanted into the hind limb of C57BL6 mice (Hallahan *et al.*, 1995b; Hallahan *et al.*, 1998; Hallahan & Virudachalam, 1999).

To determine the optimal time at which peptides bind within tumors, phage were administered at 1 hour before, at 1 hour after, and at 4 hours after irradiation of both LLC and GL261 tumors. Phage were recovered from tumors when administered 4 hours after irradiation. Phage administered 1 hour before or 1 hour after irradiation were not recovered from tumors. These data indicate that the optimal time of administration is beyond 1 hour after irradiation.

For *in vivo* panning, tumors were irradiated with 3 Gy and approximately  $10^{10}$  phage (prepared as described in Example 4) were administered by tail vein injection into each of the tumor bearing mice at 4 hours following irradiation. Tumors were recovered at one hour following  
5 injection and amplified in BL21 bacteria. Amplified phage were pooled and re-administered to a tumor-bearing mouse following tumor irradiation. The phage pool was sequentially administered to a total of 6 animals. As a control, wild type phage lacking synthetic peptide inserts were identically administered to a second experimental group of animals.

10 To determine the titer of phage binding in a tumor or in normal tissue, recovered phage were amplified in BL21 bacteria. Bacteria were plated and the number of plaques present were counted. To determine the total phage output per organ, the number of plaque forming units (PFU) on each plate was divided by the volume of phage plated and the weight of each organ.  
15 Normal variation was observed as a 2-fold difference in PFU.

In the present study, background binding within tumor blood vessels was approximately  $10^4$  phage. Phage that bound to the vasculature within irradiated tumors show enrichment in the tumor relative to other organs and enrichment in the irradiated tumor relative to the control phage without DNA  
20 insert. Phage that home to irradiated tumors showed a background level of binding in control organs that was lower than control phage without DNA insert.

Following 6 rounds of *in vivo* panning, fifty recombinant phage peptides that bound within irradiated tumors were randomly selected for  
25 further analysis. The nucleic acid sequence encoding recombinant phage was amplified by PCR using primers set forth as SEQ ID NOs:14-15 (available from Novagen of Madison, Wisconsin). An individual phage suspension was used as template. Amplified peptides were sequenced using an ABI PRISM 377 sequencer (Applied Biosystems of Foster City,  
30 California). The sequences of the encoded peptides are listed in Table 1. Several conserved subsequences were deduced from the recovered peptides and are presented in Table 2.

- 62 -

Peptide sequences recovered from both tumor types include NHVGGSSV (SEQ ID NO:1), NSLRGDGSSV (SEQ ID NO:2), and NSVGSRV (SEQ ID NO:4). Of the peptide sequences recovered from 6 irradiated tumors, 56% had the subsequence GSSV (SEQ ID NO:5), 18% had the sequence RGDGSSV (SEQ ID NO:6), and 4% had the sequence GSRV (SEQ ID NO:7). Approximately 22-40 of  $10^6$  injected phage were recovered from irradiated tumors having a peptide insert comprising the subsequence GSSV (SEQ ID NO:5). By contrast, no phage were from irradiated tumors following administration of  $10^6$  wild type phage.

10

Table 1Peptides Identified by *In Vivo* Panning of LLC and GL261 Tumors

Peptide Sequence	Number of Phage Recovered from LLC tumors (Frequency)	Number of Phage Recovered from GL261 tumors (Frequency)
NHVGGSSV (SEQ ID NO:1)	7 (28%)	12 (48%)
NSLRGDGSSV (SEQ ID NO:2)	7 (28%)	2 (8%)
NSVRGSGSGV (SEQ ID NO:3)	7 (28%)	0
NSVGSRV (SEQ ID NO:4)	1 (4%)	3 (12%)
Unique Sequences	3 (12%)	8 (32%)

Table 2Conserved Motifs within Peptides Identified by *In Vivo* Panning

Conserved Sequence	Frequency of Recovery
GSSV (SEQ ID NO:13)	56%
GSXV (SEQ ID NO:8)	78%
NSXRGXGS (SEQ ID NO:9)	32%
NSV (SEQ ID NO:10)	22%
NSXR (SEQ ID NO:11)	32%
NXVG (SEQ ID NO:12)	46%

15

### Example 6

#### Peptide Targeting in Additional Tumors

The binding properties of phage encoding NHVGGSSV (SEQ ID NO:1), NSLRGDGSSV (SEQ ID NO:2), NSVRGSGSGV (SEQ ID NO:3), and  
5 NSVGSRV (SEQ ID NO:4) were additionally characterized in a B16F0 melanoma model. Peptides set forth as SEQ ID NOs:1 and 2 bound within the melanoma, lung carcinoma, and glioma tumor models. SEQ ID NO:3 bound within glioma and melanoma, and SEQ ID NO:4 bound within lung carcinoma and glioma.

10

### Example 7

#### Characterization of Peptide Binding to Irradiated Tumors

To determine where recombinant peptides bind in tumor blood vessels, the biodistribution of biotinylated peptides was assessed. Tumors were treated with 3 Gy and biotinylated peptides were administered by tail  
15 vein at 4 hours following irradiation. Tumors were recovered 30 minutes following administration of biotinylated peptides. Tumors were snap frozen and sectioned on a cryostat. Frozen sections were then incubated with Avidin-FITC (fluorescein isothiocyanate) and imaged by fluorescent microscopy. Recombinant peptides (for example, those set forth in Table 1)  
20 were observed to bind the vascular endothelium within tumor blood vessels.

The anti- $\alpha_{2b}\beta_3$  monoclonal antibody was administered by tail vein to determine whether this receptor is required for recombinant phage binding in irradiated tumors. Phage encoding SLRGDGSV (SEQ ID NO:5) on the capsid protein were injected immediately after blocking antibody or control  
25 antibody. Phage were recovered from the tumor and controls organs and quantified by plaque formation. Radiation induced a 4-fold increase in phage binding in tumor. Blocking antibody eliminated induction of phage binding, while control antibody to P-selectin (on activated platelets) did not reduce phage binding. Thus, the tumor binding activity of targeting peptide  
30 SLRGDGSV (SEQ ID NO:5) is dependent on its interaction with the  $\alpha_{2b}\beta_3$  receptor.

### Example 8

#### *In vivo* Panning for Antibody Ligands to Radiation-Induced Molecules

A phage library comprising diverse single chain antibodies was prepared in M13 phage. The phage library was exposed to the radiation-induced neoantigens P-selectin (also called CD62P; GenBank Accession No. P98109) and/or platelet membrane glycoprotein IIB (also called CD41; GenBank Accession No. P08514) immobilized on glass slides. Phage were selected based on antigen binding, and selected phage were pooled as a biased library. For representative *in vitro* panning methods, see Fowlkes *et al.* (1992) *Biotechniques* 13:422-428; Haaparanta & Huse (1995) *Mol Divers* 1:39-52; Jung & Pluckthun (1997) *Protein Eng* 10:959-966; Peter *et al.* (2000) *Circulation* 101:1158-1164; and Holzem *et al.* (2001) *J Gen Virol* 82:9-15; Chiu *et al.* (2000) *J Agric Food Chem* 48:2614-2624.

Phage identified by *in vitro* panning were tested on Western immunoblots to confirm binding to the P-selection and platelet membrane glycoprotein IIB neoantigens. Phage that specifically bound P-selectin and platelet membrane glycoprotein IIB were subsequently used for *in vivo* panning to irradiated tumors as described in Example 5. Wild type phage were used as internal controls. Antibodies having substantial affinity for irradiated tumors were identified by observing an increased number of phage in the irradiated tumor when compared to a number of phage in a control organ (*e.g.*, liver and lung). Phage antibodies with the greatest affinity for tumors were identified using the formula: number of phage in irradiated tumor / number of phage in each organ.

Eight antibodies that bound P-selectin and fifteen antibodies that bound platelet membrane glycoprotein IIB were recovered following *in vivo* panning to irradiated tumors. Representative targeting antibodies identified by this method include the single chain antibodies set forth as SEQ ID NOs:18 and 20 (encoded by SEQ ID NOs:17 and 19, respectively), that recognize the radiation-induced neoantigens P-selectin and platelet membrane glycoprotein IIB, respectively.

### References

- The references listed below as well as all references cited in the specification are incorporated herein by reference to the extent that they supplement, explain, provide a background for or teach methodology, techniques and/or compositions employed herein.
- Aboud-Pirak E, Lesur B, Rao KS, Baurain R, Trouet À & Schneider YJ (1989) Cytotoxic activity of daunorubicin or vindesin conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells. *Biochem Pharmacol* 38:641-648.
- 10 Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, Bono M, Ferrantini M, Rozera C, Truini M, Belardelli F, Santi L & Noonan DM (2000) Inhibition of angiogenesis and vascular tumor growth by interferon- producing cells: A gene therapy approach. *Am J Pathol* 156:1381-1393.
- 15 Allen JB, Walberg MW, Edwards MC & Elledge SJ (1995) Finding prospective partners in the library: the two-hybrid system and phage display find a match. *Trends Biochem Sci* 20:511-516.
- Altschul SF, Gish W, Miller W, Myers EW & Lipman DJ (1990) Basic local alignment search tool. *J Mol Biol* 215:403-410.
- 20 Amemiya Y, Satow Y, Matsushita T, Chikawa J, Wakabayashi K, Miyahara J & Mandelkow E (1988) Storage Phosphor Detector.
- Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B & Verlander M (2000) Large-scale synthesis of peptides. *Biopolymers* 55:227-250.
- Arap W, Pasqualini R & Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. *Science* 279:377-380.
- 25 Ausubel F, ed (1995) *Short Protocols in Molecular Biology*, 3rd ed. Wiley, New York.
- Baillie CT, Winslet MC & Bradley NJ (1995) Tumour vasculature—a potential therapeutic target. *Br J Cancer* 72:257-267.
- 30 Barton GJ (1998) Protein sequence alignment techniques. *Acta Crystallogr D Biol Crystallogr* 54:1139-1146.

- Batzer MA, Carlton JE & Deininger PL (1991) Enhanced evolutionary PCR using oligonucleotides with inosine at the 3'- terminus. *Nucleic Acids Res* 19:5081.
- Bauminger S & Wilchek M (1980) The use of carbodiimides in the  
5 preparation of immunizing conjugates. *Methods Enzymol* 70:151-159.
- Becerril B, Poul MA & Marks JD (1999) Toward selection of internalizing antibodies from phage libraries. *Biochem Biophys Res Commun* 255:386-393.
- Bendixen C, Gangloff S & Rothstein R (1994) A yeast mating-selection  
10 scheme for detection of protein-protein interactions. *Nucleic Acids Res* 22:1778-1779.
- Bodanszky M (1993) *Principles of Peptide Synthesis*, 2nd rev. ed. Springer-Verlag, Berlin/New York.
- Boerman OC, Oyen WJ & Corstens FH (2000) Radio-labeled receptor-  
15 binding peptides: a new class of radiopharmaceuticals. *Semin Nucl Med* 30:195-208.
- Brenner S & Lerner RA (1992) Encoded combinatorial chemistry. *Proc Natl Acad Sci U S A* 89:5381-5383.
- Brent R & Finley RL, Jr. (1997) Understanding gene and allele function with  
20 two-hybrid methods. *Annu Rev Genet* 31:663-704.
- Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M & Meredith R (1995) Fractionated radioimmunotherapy of human colon carcinoma xenografts with <sup>131</sup>I-labeled monoclonal antibody CC49. *Cancer Res* 55:5881s-5887s.
- 25 Burg MA, Pasqualini R, Arap W, Ruoslahti E & Stallcup WB (1999) NG2 proteoglycan-binding peptides target tumor neovasculature. *Cancer Res* 59:2869-2874.
- Carninci P, Kvam C, Kitamura A, Ohsumi T, Okazaki Y, Itoh M, Kamiya M, Shibata K, Sasaki N, Izawa M, Muramatsu M, Hayashizaki Y &  
30 Schneider C (1996) High-efficiency full-length cDNA cloning by biotinylated CAP trapper. *Genomics* 37:327-336.

- Carpizo D & Iruela-Arispe ML (2000) Endogenous regulators of angiogenesis--emphasis on proteins with thrombospondin--type I motifs. *Cancer Metastasis Rev* 19:159-165.
- 5 Chattopadhyay S, Das MK, Vanaja R & Ramamoorthy N (2001) Purification and stabilization of <sup>99m</sup>Tc-d,l-HMPAO: role of organic extractants. *Nucl Med Biol* 28:741-744.
- Cheng PW (1996) Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. *Hum Gene Ther* 7:275-282.
- 10 Cheng S, Craig WS, Mullen D, Tschopp JF, Dixon D & Pierschbacher MD (1994) Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin  $\alpha$ IIb  $\beta$ 3 antagonists. *J Med Chem* 37:1-8.
- Chiu YW, Chen R, Li QX & Karu AE (2000) Derivation and properties of recombinant Fab antibodies to coplanar polychlorinated biphenyls. *J Agric Food Chem* 48:2614-2624.
- 15 Clapp C, Martial JA, Guzman RC, Rentier-Delure F & Weiner RI (1993) The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. *Endocrinology* 133:1292-1299.
- 20 Coatney RW (2001) Ultrasound imaging: principles and applications in rodent research. *Ilar J* 42:233-247.
- Cohen BA, Colas P & Brent R (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. *Proc Natl Acad Sci U S A* 95:14272-14277.
- 25 Corringier PJ, Weng JH, Ducos B, Durieux C, Boudeau P, Bohme A & Roques BP (1993) CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. *J Med Chem* 36:166-172.
- Dameron KM, Volpert OV, Tainsky MA & Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. *Science* 265:1582-1584.
- 30

- Deutscher MP (1990) Guide to Protein Purification, Academic Press, San Diego.
- Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, Dewanjee S, Serafini AN, Lopez DM & Sfakianakis GN (1994) Noninvasive imaging of c-myc oncogene messenger RNA with indium-111- antisense probes in  
5 a mammary tumor-bearing mouse model. J Nucl Med 35:1054-1063.
- Dias S, Thomas H & Balkwill F (1998) Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer 75:151-157.
- 10 Dillman RO, Johnson DE, Ogden J & Beidler D (1989) Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. Mol Biother 1:250-255.
- Donnelly EF, Geng L, Wojcicki WE, Fleischer AC & Hallahan DE (2001)  
15 Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 219:166-170.
- Eijan AM, Davel L, Oisgold-Daga S & de Lustig ES (1991) Modulation of tumor-induced angiogenesis by proteins of extracellular matrix. Mol  
20 Biother 3:38-40.
- Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE & Pasqualini R (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-1038.
- 25 European Patent No. 0 439 095
- Fields GB & Noble RL (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161-214.
- Fjalling M, Andersson P, Forssell-Aronsson E, Gretarsdottir J, Johansson V,  
30 Tisell LE, Wangberg B, Nilsson O, Berg G, Michanek A, Lindstedt G & Ahlman H (1996) Systemic radionuclide therapy using indium-111-

- DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. *J Nucl Med* 37:1519-1521.
- Fields S & Song O (1989) A novel genetic system to detect protein-protein interactions. *Nature* 340:245-246.
- 5 Fitzpatrick JJ & Garnett MC (1995) Design, synthesis and in vitro testing of methotrexate carrier conjugates linked via oligopeptide spacers. *Anticancer Drug Des* 10:1-9.
- Fowlkes DM, Adams MD, Fowler VA & Kay BK (1992) Multipurpose vectors for peptide expression on the M13 viral surface. *Biotechniques* 10 13:422-428.
- Fraser SE (1996) Ionophoretic dye labeling of embryonic cells. *Methods Cell Biol* 51:147-160.
- Fuller KJ, Morse MA, White JH, Dowell SJ & Sims MJ (1998) Development of a yeast trihybrid screen using stable yeast strains and regulated protein expression. *Biotechniques* 15 25:85-88, 90-82.
- Garbay-Jaureguiberry C, Ficheux D & Roques BP (1992) Solid phase synthesis of peptides containing the non-hydrolysable analog of (O)phosphotyrosine, p(CH<sub>2</sub>PO<sub>3</sub>H<sub>2</sub>)Phe. Application to the synthesis of 344-357 sequences of the beta 2 adrenergic receptor. *Int J Pept Protein Res* 20 39:523-527.
- Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H & Hallahan DE (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. *Cancer Res* 61:2413-2419.
- 25 Glover DM & Hames BD (1995) *DNA Cloning: A Practical Approach*, 2nd ed. IRL Press at Oxford University Press, Oxford/New York.
- Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA & Curiel DT (1997) Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. 30 *Cancer Res* 57:1447-1451.

- Haaparanta T & Huse WD (1995) A combinatorial method for constructing libraries of long peptides displayed by filamentous phage. *Mol Divers* 1:39-52.
- 5      Hallahan D, Kuchibhotla J & Wyble C (1996) Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. *Cancer Res* 56:5150-5155.
- Hallahan D, Clark ET, Kuchibhotla J, Gewertz BL & Collins T (1995a) E-selectin gene induction by ionizing radiation is independent of cytokine induction. *Biochem Biophys Res Commun* 217:784-795.
- 10    Hallahan DE & Virudachalam S (1999) Accumulation of P-selectin in the lumen of irradiated blood vessels. *Radiat Res* 152:6-13.
- Hallahan DE, Staba-Hogan MJ, Virudachalam S & Kolchinsky A (1998) X-ray-induced P-selectin localization to the lumen of tumor blood vessels. *Cancer Res* 58:5216-5220.
- 15    Hallahan DE, Geng L, Cmelak AJ, Chakravarthy AB, Martin W, Scarfone C & Gonzalez A (2001a) Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature. *J Control Release* 74:183-191.
- Hallahan DE, Qu S, Geng L, Cmelak A, Chakravarthy A, Martin W, Scarfone C & Giorgio T (2001b) Radiation-Mediated Control of Drug Delivery. *Am J Clin Oncol*: in press.
- 20      Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW & Weichselbaum RR (1995b) Spatial and temporal control of gene therapy using ionizing radiation. *Nat Med* 1:786-791.
- 25      Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL & et al. (1994) Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide- conjugated monoclonal antibody 212Bi-anti-Tac. *Cancer Res* 54:4362-4370.
- 30

- Hawiger J & Timmons S (1992) Binding of fibrinogen and von Willebrand factor to platelet glycoprotein IIb-IIIa complex. *Methods Enzymol* 215:228-243.
- Hawiger J, Kloczewiak M, Bednarek MA & Timmons S (1989) Platelet  
5 receptor recognition domains on the alpha chain of human fibrinogen: structure-function analysis. *Biochemistry* 28:2909-2914.
- Healy JM, Murayama O, Maeda T, Yoshino K, Sekiguchi K & Kikuchi M (1995) Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. *Biochemistry* 34:3948-3955.
- 10 Henikoff JG, Pietrovski S, McCallum CM & Henikoff S (2000) Blocks-based methods for detecting protein homology. *Electrophoresis* 21:1700-1706.
- Henikoff S & Henikoff JG (1992) Amino acid substitution matrices from protein blocks. *Proc Natl Acad Sci U S A* 89:10915-10919.
- 15 Henn TF, Garnett MC, Chhabra SR, Bycroft BW & Baldwin RW (1993) Synthesis of 2'-deoxyuridine and 5-fluoro-2'-deoxyuridine derivatives and evaluation in antibody targeting studies. *J Med Chem* 36:1570-1579.
- Heredia M, Santacana M & Valverde F (1991) A method using Dil to study  
20 the connectivity of cortical transplants. *J Neurosci Methods* 36:17-25.
- Hnatowich DJ, Mardirossian G, Fogarasi M, Sano T, Smith CL, Cantor CR, Rusckowski M & Winnard P, Jr. (1996) Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice. *J Pharmacol Exp*  
25 *Ther* 276:326-334.
- Holzem A, Nahring JM & Fischer R (2001) Rapid identification of a tobacco mosaic virus epitope by using a coat protein gene-fragment-pVIII fusion library. *J Gen Virol* 82:9-15.
- Huang CC, Novak WR, Babbitt PC, Jewett AI, Ferrin TE & Klein TE (2000)  
30 Integrated tools for structural and sequence alignment and analysis. *Pac Symp Biocomput*:230-241.

- Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H & Folkman J  
(1990) Synthetic analogues of fumagillin that inhibit angiogenesis and  
suppress tumour growth. *Nature* 348:555-557.
- Ishikawa E (1999) *Ultrasensitive and rapid enzyme immunoassay*. Elsevier,  
5 Amsterdam/New York.
- Ito T, Qiu H, Collins JA, Brill AB, Johnson DK & Griffin TW (1991) Preclinical  
assessments of 90Y-labeled C110 anti-carcinoembryonic antigen  
immunotoxin: a therapeutic immunoconjugate for human colon  
cancer. *Cancer Res* 51:255-260.
- 10 Julien M, Kajiji S, Kaback RH & Gros P (2000) Simple purification of highly  
active biotinylated P-glycoprotein: enantiomer-specific modulation of  
drug-stimulated ATPase activity. *Biochemistry* 39:75-85.
- Jung S & Pluckthun A (1997) Improving in vivo folding and stability of a  
single-chain Fv antibody fragment by loop grafting. *Protein Eng*  
15 10:959-966.
- Karlin S & Altschul SF (1993) Applications and statistics for multiple high-  
scoring segments in molecular sequences. *Proc Natl Acad Sci U S A*  
90:5873-5877.
- Kirk CJ & Mule JJ (2000) Gene-modified dendritic cells for use in tumor  
20 vaccines. *Hum Gene Ther* 11:797-806.
- Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC &  
Papahadjopoulos D (1997) Sterically stabilized anti-HER2  
immunoliposomes: design and targeting to human breast cancer cells  
in vitro. *Biochemistry* 36:66-75.
- 25 Koivunen E, Gay DA & Ruoslahti E (1993) Selection of peptides binding to  
the alpha 5 beta 1 integrin from phage display library. *J Biol Chem*  
268:20205-20210.
- Koivunen E, Wang B & Ruoslahti E (1994) Isolation of a highly specific  
ligand for the alpha 5 beta 1 integrin from a phage display library. *J*  
30 *Cell Biol* 124:373-380.

- Kolonin MG & Finley RL, Jr. (1998) Targeting cyclin-dependent kinases in *Drosophila* with peptide aptamers. *Proc Natl Acad Sci U S A* 95:14266-14271.
- 5 Kosfeld MD & Frazier WA (1993) Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin. *J Biol Chem* 268:8808-8814.
- Krauer KG, McKenzie IF & Pietersz GA (1992) Antitumor effect of 2'-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts. *Cancer Res* 52:132-137.
- 10 Krenning EP & de Jong M (2000) Therapeutic use of radiolabelled peptides. *Ann Oncol* 11:267-271.
- Kwekkeboom D, Krenning EP & de Jong M (2000) Peptide receptor imaging and therapy. *J Nucl Med* 41:1704-1713.
- Kyte J & Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. *J Mol Biol* 157:105-132.
- 15 Law B (1996) *Immunoassay: A Practical Guide*. Taylor & Francis, London/Bristol, Pennsylvania.
- Lau A, Berube G & Ford CH (1995) Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents. *Bioorg Med Chem* 3:1299-1304.
- 20 Lecrenier N, Foury F & Goffeau A (1998) Two-hybrid systematic screening of the yeast proteome. *Bioessays* 20:1-5.
- Lees W (2001) Ultrasound imaging in three and four dimensions. *Semin Ultrasound CT MR* 22:85-105.
- 25 Leibel SA & Phillips TL (1998) *Textbook of Radiation Oncology*. Saunders, Philadelphia.
- Licha K, Riefke B, Ntziachristos V, Becker A, Chance B & Semmler W (2000) Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic
- 30 in vivo characterization. *Photochem Photobiol* 72:392-398.
- Lu Z, Murray KS, Van Cleave V, LaVallie ER, Stahl ML & McCoy JM (1995) Expression of thioredoxin random peptide libraries on the *Escherichia*

coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. *Biotechnology (N Y)* 13:366-372.

- 5 Mackensen A, Lindemann A & Mertelsmann R (1997) Immunostimulatory cytokines in somatic cells and gene therapy of cancer. *Cytokine Growth Factor Rev* 8:119-128.
- Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF & Sharpe RJ (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. *Science* 247:77-79.
- 10 Manome Y, Abe M, Hagen MF, Fine HA & Kufe DW (1994) Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. *Cancer Res* 54:5408-5413.
- Manson MM (1992) *Immunochemical Protocols*. Humana Press, Totowa, New Jersey.
- 15 Martodam RR, Twumasi DY, Liener IE, Powers JC, Nishino N & Krejcarek G (1979) Albumin microspheres as carrier of an inhibitor of leukocyte elastase: potential therapeutic agent for emphysema. *Proc Natl Acad Sci U S A* 76:2128-2132.
- 20 McOmie JFW. (1973) *Protective Groups in Organic Chemistry*, Plenum Press, London, New York.
- Merrifield RB (1969) Solid-phase peptide synthesis. *Adv Enzymol Relat Areas Mol Biol* 32:221-296.
- Nabel G (1997) *Vectors for Gene Therapy*. In: *Current Protocols in Human Genetics*, John Wiley & Sons, New York.
- 25 Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, Melero I & Prieto J (2000) Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. *J Immunol* 164:3112-3122.
- 30

- Needleman SB & Wunsch CD (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. *J Mol Biol* 48:443-453.
- 5 Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L & Winter G (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. *Nat Biotechnol* 15:1271-1275.
- 10 Nomura T & Hasegawa H (2000) Chemokines and anti-cancer immunotherapy: anti-tumor effect of EBI1- ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC). *Anticancer Res* 20:4073-4080.
- 15 O'Byrne KJ, Dalglish AG, Browning MJ, Steward WP & Harris AL (2000) The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. *Eur J Cancer* 36:151-169.
- O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH & Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. *Cell* 79:315-328.
- 20 O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR & Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* 88:277-285.
- 25 Ohtsuka E, Matsuki S, Ikehara M, Takahashi Y & Matsubara K (1985) An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions. *J Biol Chem* 260:2605-2608.
- Park JW, Hong K, Kirpotin DB, Papahadjopoulos D & Benz CC (1997) Immunoliposomes for cancer treatment. *Adv Pharmacol* 40:399-435.
- 30 Pasqualini R & Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. *Nature* 380:364-366.

- Pasqualini R, Koivunen E & Ruoslahti E (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. *Nat Biotechnol* 15:542-546.
- 5 Pavone V, Di Blasio B, Lombardi A, Maglio O, Isernia C, Pedone C, Benedetti E, Altmann E & Mutter M (1993) Non coded C alpha, alpha-disubstituted amino acids. X-ray diffraction analysis of a dipeptide containing (S)-alpha-methylserine. *Int J Pept Protein Res* 41:15-20.
- Pearson WR & Lipman DJ (1988) Improved tools for biological sequence comparison. *Proc Natl Acad Sci U S A* 85:2444-2448.
- 10 Peter K, Graeber J, Kipriyanov S, Zewe-Welschhof M, Runge MS, Kubler W, Little M & Bode C (2000) Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. *Circulation* 101:1158-1164.
- 15 Pierschbacher MD & Ruoslahti E (1987) Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. *J Biol Chem* 262:17294-17298.
- Pomper MG & Port JD (2000) New techniques in MR imaging of brain tumors. *Magn Reson Imaging Clin N Am* 8:691-713.
- 20 Ragnarson B, Bengtsson L & Haegerstrand A (1992) Labeling with fluorescent carbocyanine dyes of cultured endothelial and smooth muscle cells by growth in dye-containing medium. *Histochemistry* 97:329-333.
- 25 Rehrauer WM, Lavery PE, Palmer EL, Singh RN & Kowalczykowski SC (1996) Interaction of Escherichia coli RecA protein with LexA repressor. I. LexA repressor cleavage is competitive with binding of a secondary DNA molecule. *J Biol Chem* 271:23865-23873.
- 30 Rossolini GM, Cresti S, Ingianni A, Cattani P, Riccio ML & Satta G (1994) Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information. *Mol Cell Probes* 8:91-98.

- Rovaris M, Comi G & Filippi M (2001) The role of non-conventional MR techniques to study multiple sclerosis patients. *J Neurol Sci* 186 Suppl 1:S3-9.
- 5 Rowland AJ, Pietersz GA & McKenzie IF (1993) Preclinical investigation of the antitumour effects of anti-CD19- idarubicin immunoconjugates. *Cancer Immunol Immunother* 37:195-202.
- Sagiuchi T, Ishii K, Asano Y, Aoki Y, Woodhams R, Yanaihara H, Kan S & Hayakawa K (2001) Transient seizure activity demonstrated by Tc-99m HMPAO SPECT and diffusion-weighted MR imaging. *Ann Nucl Med* 15:267-270.
- 10 Sakamoto N, Iwahana M, Tanaka NG & Osada Y (1991) Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH<sub>2</sub>. *Cancer Res* 51:903-906.
- Saltzman WM & Fung LK (1997) Polymeric implants for cancer chemotherapy. *Adv Drug Deliv Rev* 26:209-230.
- 15 Sambrook J & Russell DW (2001) *Molecular Cloning: a Laboratory Manual*, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
- Saqi MA, Wild DL & Hartshorn MJ (1999) Protein analyst--a distributed object environment for protein sequence and structure analysis. *Bioinformatics* 15:521-522.
- 20 Schechter B, Arnon R, Wilchek M, Schlessinger J, Hurwitz E, Aboud-Pirak E & Sela M (1991) Indirect immunotargeting of cis-Pt to human epidermoid carcinoma KB using the avidin-biotin system. *Int J Cancer* 48:167-172.
- 25 Schneider CH & Eberle AN (1993) *Peptides, 1992: Proceedings of the Twenty-Second European Peptide Symposium, September 13-19, 1992, Interlaken, Switzerland, Escom, Leiden.*
- Schröder E & Lübke K (1965) *The Peptides*, Academic Press, New York.
- 30 Schwendener R (1992) Liposomes and Immunoliposomes as Carriers for Cytostatic Drugs, Magnetic Resonance Contrast Agents, and Fluorescent Chelates. *Chimia* 46:69-77.

- Shawler DL, Johnson DE, Sweet MD, Myers LJ, Tudor SD, Beidler DE, Koziol JA & Dillman RO (1988) Preclinical trials using an immunoconjugate of T101 and methotrexate in an athymic mouse/human T-cell tumor model. *J Biol Response Mod* 7:608-618.
- 5    Shen T, Weissleder R, Papisov M, Bogdanov A, Jr. & Brady TJ (1993) Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. *Magn Reson Med* 29:599-604.
- Shih LB, Goldenberg DM, Xuan H, Lu HW, Mattes MJ & Hall TC (1994) Internalization of an intact doxorubicin immunoconjugate. *Cancer Immunol Immunother* 38:92-98.
- 10    Silhavy TJ, Berman ML, Enquist LW & Cold Spring Harbor Laboratory. (1984) Experiments with Gene Fusions. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
- Sivam GP, Martin PJ, Reisfeld RA & Mueller BM (1995) Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. *Cancer Res* 55:2352-2356.
- 15    Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. *Science* 228:1315-1317.
- 20    Smith TF & Waterman M (1981) Comparison of Biosequences. *Adv Appl Math* 2:482-489.
- Smyth MJ, Pietersz GA & McKenzie IF (1987) The cellular uptake and cytotoxicity of chlorambucil-monoclonal antibody conjugates. *Immunol Cell Biol* 65:315-321.
- 25    Staba MJ, Wickham TJ, Kovesdi I & Hallahan DE (2000) Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. *Cancer Gene Ther* 7:13-19.
- Starling JJ, Maciak RS, Hinson NA, Nichols CL, Briggs SL, Laguzza BC, Smith W & Corvalan JR (1992) In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which
- 30

- bind to three distinct epitopes of carcinoembryonic antigen. *Bioconjug Chem* 3:315-322.
- Stewart JM & Young JD (1969) *Solid Phase Peptide Synthesis*, Freeman, San Francisco.
- 5 Tang XB & Casey JR (1999) Trapping of inhibitor-induced conformational changes in the erythrocyte membrane anion exchanger AE1. *Biochemistry* 38:14565-14572.
- Tavitian B, Terrazzino S, Kuhnast B, Marzabal S, Stettler O, Dolle F, Deverre JR, Jobert A, Hinnen F, Bendriem B, Crouzel C & Di
- 10 Giamberardino L (1998) In vivo imaging of oligonucleotides with positron emission tomography. *Nat Med* 4:467-471.
- Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes*. Elsevier, New York.
- Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ & Bouck N
- 15 (1993) Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. *J Cell Biol* 122:497-511.
- Tung CH, Zhu T, Lackland H & Stein S (1992) An acridine amino acid derivative for use in Fmoc peptide synthesis. *Pept Res* 5:115-118.
- 20 Urge L, Otvos L, Jr., Lang E, Wroblewski K, Laczko I & Hollosi M (1992) Fmoc-protected, glycosylated asparagines potentially useful as reagents in the solid-phase synthesis of N-glycopeptides. *Carbohydr Res* 235:83-93
- U.S. Patent No. 4,235,871
- 25 U.S. Patent No. 4,244,946
- U.S. Patent No. 4,551,482
- U.S. Patent No. 4,554,101
- U.S. Patent No. 5,011,634
- U.S. Patent No. 5,088,499
- 30 U.S. Patent No. 5,147,631
- U.S. Patent No. 5,168,037
- U.S. Patent No. 5,223,409

- 80 -

- U.S. Patent No. 5,234,933
- U.S. Patent No. 5,264,563
- U.S. Patent No. 5,326,902
- U.S. Patent No. 5,490,840
- 5 U.S. Patent No. 5,498,538
- U.S. Patent No. 5,508,020
- U.S. Patent No. 5,510,103
- U.S. Patent No. 5,645,815
- U.S. Patent No. 5,578,629
- 10 U.S. Patent No. 5,574,172
- U.S. Patent No. 5,650, 489
- U.S. Patent No. 5,651,991
- U.S. Patent No. 5,667,988
- U.S. Patent No. 5,688,931
- 15 U.S. Patent No. 5,702,892
- U.S. Patent No. 5,707,605
- U.S. Patent No. 5,714,166
- U.S. Patent No. 5,738,837
- U.S. Patent No. 5,738,996
- 20 U.S. Patent No. 5,747,334
- U.S. Patent No. 5,756,291
- U.S. Patent No. 5,780,225
- U.S. Patent No. 5,786,387
- U.S. Patent No. 5,811,392
- 25 U.S. Patent No. 5,811,512
- U.S. Patent No. 5,811,515
- U.S. Patent No. 5,817,757
- U.S. Patent No. 5,817,879
- U.S. Patent No. 5,824,483
- 30 U.S. Patent No. 5,830,856
- U.S. Patent No. 5,840,479
- U.S. Patent No. 5,580,717

- U.S. Patent No. 5,851,818
- U.S. Patent No. 5,855,900
- U.S. Patent No. 5,858,410
- U.S. Patent No. 5,858,670
- 5 U.S. Patent No. 5,858,784
- U.S. Patent No. 5,865,754
- U.S. Patent No. 5,922,356
- U.S. Patent No. 5,948,635
- U.S. Patent No. 5,922,545
- 10 U.S. Patent No. 5,928,627
- U.S. Patent No. 5,948,767
- U.S. Patent No. 5,994,392
- U.S. Patent No. 6,013,638
- U.S. Patent No. 6,015,561
- 15 U.S. Patent No. 6,015,881
- U.S. Patent No. 6,022,737
- U.S. Patent No. 6,024,938
- U.S. Patent No. 6,031,071
- U.S. Patent No. 6,083,486
- 20 U.S. Patent No. 6,056,938
- U.S. Patent No. 6,057,098
- U.S. Patent No. 6,068,829
- U.S. Patent No. 6,071,890
- U.S. Patent No. 6,080,384
- 25 U.S. Patent No. 6,106,866
- U.S. Patent No. 6,107,059
- U.S. Patent No. 6,132,766
- U.S. Patent No. 6,136,295
- U.S. Patent No. 6,156,511
- 30 U.S. Patent No. 6,159,443
- U.S. Patent No. 6,168,912
- U.S. Patent No. 6,174,708

- U.S. Patent No. 6,180,348  
U.S. Patent No. 6,197,333  
U.S. Patent No. 6,200,598  
U.S. Patent No. 6,210,707  
5 U.S. Patent No. 6,214,553  
U.S. Patent No. 6,217,886  
U.S. Patent No. 6,221,018  
U.S. Patent No. 6,225,447  
U.S. Patent No. 6,231,834  
10 U.S. Patent No. 6,245,318  
U.S. Patent No. 6,246,901  
U.S. Patent No. 6,254,852  
Vasavada HA, Ganguly S, Germino FJ, Wang ZX & Weissman SM (1991) A  
contingent replication assay for the detection of protein-protein  
15 interactions in animal cells. Proc Natl Acad Sci U S A 88:10686-  
10690.  
Vinogradov SA, Lo LW, Jenkins WT, Evans SM, Koch C & Wilson DF (1996)  
Noninvasive imaging of the distribution in oxygen in tissue in vivo  
using near-infrared phosphors. Biophys J 70:1609-1617.  
20 Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T,  
Angelberger P, Raderer M, Andreae F, Kurtaran A & Dudczak R  
(2001) New trends in peptide receptor radioligands. Q J Nucl Med  
45:153-159.  
Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ & Folkman J  
25 (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl  
Cancer Inst 87:581-586.  
Walther W & Stein U (1999) Therapeutic genes for cancer gene therapy. Mol  
Biotechnol 13:21-28.  
Weissleder R, Bogdanov A & Papisov M (1992) Drug targeting in magnetic  
30 resonance imaging. Magn Reson Q 8:55-63.

- Weissleder R, Tung CH, Mahmood U & Bogdanov A, Jr. (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. *Nat Biotechnol* 17:375-378.
- Wickham TJ, Carrion ME & Kovesdi I (1995) Targeting of adenovirus penton  
5 base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. *Gene Ther* 2:750-756.
- Wilbur DS (1992) Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. *Bioconjug Chem* 3:433-470
- 10 WO 01/09611  
WO 93/25521  
WO 98/10795  
WO 99/54728
- Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J & Fassler J (1991) Somatostatin analogues inhibit  
15 angiogenesis in the chick chorioallantoic membrane. *J Surg Res* 50:245-251.
- Yang M, Wu Z & Fields S (1995) Protein-peptide interactions analyzed with the yeast two-hybrid system. *Nucleic Acids Res* 23:1152-1156.
- 20 Yoo TM, Chang HK, Choi CW, Webber KO, Le N, Kim IS, Eckelman WC, Pastan I, Carrasquillo JA & Paik CH (1997) Technetium-99m labeling and biodistribution of anti-TAC disulfide- stabilized Fv fragment. *J Nucl Med* 38:294-300.

25 It will be understood that various details of the invention can be changed without departing from the scope of the invention. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation--the invention being defined by the claims appended hereto.

30

CLAIMS

What is claimed is:

1. A method for identifying a molecule that binds an irradiated tumor in a subject, the method comprising:
  - 5 (a) exposing a tumor to ionizing radiation;
  - (b) administering to a subject a library of diverse molecules; and
  - (c) isolating one or more molecules of the library from the tumor, whereby a molecule that binds an irradiated tumor is identified.
2. The method of claim 1, wherein the exposing comprises  
10 exposing the tumor to less than about 2 Gy ionizing radiation.
3. The method of claim 1, wherein the exposing comprises exposing the tumor to at least about 2 Gy ionizing radiation.
4. The method of claim 3, wherein the exposing comprises exposing the tumor to about 10 Gy to about 20 Gy ionizing radiation.
- 15 5. The method of claim 1, wherein the administering further comprises administering the library to isolated tumor cells or to isolated proteins prior to administering the library to the subject.
6. The method of claim 1, wherein the administering comprises administering the library by intravascular provision.
- 20 7. The method of claim 1, wherein the administering comprises administering the library subsequent to radiation exposure.
8. The method of claim 7, wherein the administering comprises administering the library 0 hours to about 24 hours following radiation exposure.
- 25 9. The method of claim 8, wherein the administering comprises administering the library about 4 hours to about 24 hours following radiation exposure.
10. The method of claim 1, wherein the subject is a warm-blooded vertebrate.
- 30 11. The method of claim 10, wherein the subject is a human.
12. The method of claim 1, wherein the library of diverse molecules comprises a library of ten or more diverse molecules.

13. The method of claim 12, wherein the library of diverse molecules comprises a library of one hundred or more diverse molecules.

14. The method of claim 13, wherein the library of diverse molecules comprises a library of a billion or more diverse molecules.

5        15. The method of claim 1, wherein the library of diverse molecules comprises a library of molecules selected from the group consisting of peptides, peptide mimetics, proteins, antibodies or fragments thereof, small molecules, nucleic acids, and combinations thereof.

10       16. The method of claim 15, wherein the library of diverse molecules comprises a library of peptides, antibodies, or a combination thereof.

17. The method of claim 1, wherein the molecule that binds an irradiated tumor comprises a ligand that binds a tumor cell, an endothelial cell associated with tumor vasculature, or a blood component.

15       18. The method of claim 1, wherein each of the exposing, administering, and isolating is repeated one or more times.

19. A molecule identified by the method of claim 1.

20. A method for identifying a molecule that binds an irradiated tumor in a subject comprising:

- 20       (a) exposing a tumor and a control tissue to ionizing radiation;
- (b) administering to the tumor and to the control tissue a library of diverse molecules;
- (c) detecting one or more molecules of the library that bind to the tumor and that substantially lack binding to the control tissue, whereby a molecule that binds an irradiated tumor is identified.
- 25

21. The method of claim 20, wherein the exposing comprises exposing the tumor to less than about 2 Gy ionizing radiation.

22. The method of claim 21, wherein the exposing comprises exposing the tumor to at least about 2 Gy ionizing radiation.

30       23. The method of claim 22, wherein the exposing comprises exposing the tumor to about 10 Gy to about 20 Gy ionizing radiation.

24. The method of claim 20, wherein the administering further comprises administering the library to isolated tumor cells or to isolated proteins prior to administering the library to the subject.

25. The method of claim 20, wherein the library of diverse  
5 molecules comprises a library of ten or more diverse molecules.

26. The method of claim 25, wherein the library of diverse molecules comprises a library of one hundred or more diverse molecules.

27. The method of claim 26, wherein the library of diverse molecules comprises a library of a billion or more diverse molecules.

10 28. The method of claim 20, wherein the library of diverse molecules comprises a library of molecules selected from the group consisting of peptides, peptide mimetics, proteins, antibodies or fragments thereof, small molecules, nucleic acids, and combinations thereof.

15 29. The method of claim 28, wherein the library of diverse molecules comprises a library of peptides, antibodies, or a combination thereof.

30. The method of claim 20, wherein the molecule that binds an irradiated tumor comprises a ligand that binds a tumor cell, an endothelial cell associated with tumor vasculature, or a blood component.

20 31. The method of claim 20, further comprising:  
(a) isolating the tumor and the control tissue, or fractions thereof; and  
(b) administering the library to the isolated tumor and to the control tissue, or fractions thereof, *in vitro*.

25 32. A molecule identified by the method of claim 20.

33. A method for preparing a composition for x-ray-guided drug delivery, the method comprising:

30 (a) performing *in vivo* panning of claim 1, whereby a targeting ligand that binds a radiation-inducible tumor molecule is identified; and  
(b) conjugating the targeting ligand to a drug, whereby a composition for x-ray-guided drug delivery is prepared.

34. A method for preparing a composition for x-ray-guided drug delivery, the method comprising:

- 5 (a) performing *in vivo* panning of claim 20, whereby a targeting ligand that binds a radiation-inducible tumor molecule is identified; and
- (b) conjugating the targeting ligand to a drug, whereby a composition for x-ray-guided drug delivery is prepared.

35. A composition for x-ray guided drug delivery comprising one or more targeting ligands identified by *in vivo* panning, wherein the one or more  
10 targeting ligands each bind to an irradiated tumor.

36. The composition of claim 35, wherein the one or more targeting ligands comprises a peptide comprising an amino acid sequence of any one of SEQ ID NOs:1-5, or combinations thereof.

37. The composition of claim 35, wherein the one or more  
15 targeting ligands comprises a peptide comprising an amino acid sequence of any one of SEQ ID NOs:1-13, or combinations thereof.

38. The composition of claim 35, wherein the one or more targeting ligands comprises a single chain antibody comprising:

- 20 (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:18 or 20;
- (b) a polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO:18 or 20;
- (c) a polypeptide encoded by a nucleotide sequence of SEQ ID NO:17 or 19;
- 25 (d) a polypeptide encoded by a nucleotide sequence substantially identical to SEQ ID NO:17 or 19; or
- (e) combinations thereof.

39. The composition of claim 35, wherein the irradiated tumor comprises a tumor exposed to less than about 2 Gy ionizing radiation.

30 40. The composition of claim 39, wherein the irradiated tumor comprises a tumor exposed to at least about 2 Gy ionizing radiation.

- 88 -

41. The composition of claim 40, wherein the irradiated tumor comprises a tumor exposed to about 10 Gy to about 20 Gy ionizing radiation.

5 42. The composition of claim 35, wherein the targeting ligand binds to an irradiated glioma, a melanoma, or lung carcinoma.

43. The composition of claim 35, wherein the targeting ligand binds to an irradiated tumor of two or more tumor types.

44. The composition of claim 43, wherein the targeting ligand binds to an irradiated tumor of three or more tumor types.

10 45. The composition of claim 44, wherein the targeting ligand binds to an irradiated glioma, a melanoma, and a lung carcinoma.

46. The composition of claim 35, further comprising a detectable label.

15 47. The composition of claim 46, wherein the detectable label is detectable *in vivo*.

48. The composition of claim 47, wherein the detectable label comprises a label that can be detected using magnetic resonance imaging, scintigraphic imaging, ultrasound, or fluorescence.

20 49. The composition of claim 48, wherein the label that can be detected using scintigraphic imaging comprises a radionuclide label.

50. The composition of claim 49, wherein the radionuclide label comprises  $^{131}\text{I}$  or  $^{99\text{m}}\text{Tc}$ .

51. The composition of claim 35, further comprising a therapeutic agent.

25 52. The composition of claim 51, wherein the therapeutic agent is selected from the group consisting of a radionuclide, a cytotoxin, a therapeutic gene, and a chemotherapeutic agent.

53. The composition of claim 35, further comprising a drug carrier.

30 54. The composition of claim 53, wherein the drug carrier is selected from the group consisting of a viral vector, a liposome, a plasmid, a microcapsule, and combinations thereof.

55. The composition of claim 54, wherein the drug carrier comprises a liposome or a microsphere.

56. The composition of claim 51, further comprising a detectable label.

5 57. The composition of claim 56, wherein the detectable label comprises a label that can be detected using magnetic resonance imaging, scintigraphic imaging, ultrasound, or fluorescence.

58. The composition of claim 57, wherein the label that can be detected using scintigraphic imaging comprises a radionuclide label.

10 59. The composition of claim 58, wherein the radionuclide label comprises  $^{131}\text{I}$  or  $^{99\text{m}}\text{Tc}$ .

60. A method for detecting a tumor in a subject comprising:

(a) exposing a suspected tumor to ionizing radiation;

15 (b) administering to the subject one or more targeting ligands identified by *in vivo* panning, wherein the one or more targeting ligands binds to an irradiated tumor, and wherein the one or more targeting ligands comprises a detectable label; and

(c) detecting the detectable label, whereby a tumor is diagnosed.

20 61. The method of claim 60, wherein the exposing comprises exposing the tumor to less than about 2 Gy ionizing radiation.

62. The method of claim 61, wherein the exposing comprises exposing the tumor to at least about 2 Gy ionizing radiation.

63. The method of claim 62, wherein the exposing comprises exposing the tumor to about 10 Gy to about 20 Gy ionizing radiation.

25 64. The method of claim 61, wherein the administering comprises administering the targeting ligand by intravascular provision.

65. The method of claim 60, wherein the administering comprises administering the targeting ligand subsequent to radiation exposure.

30 66. The method of claim 65, wherein the administering comprises administering the targeting ligand 0 hours to about 24 hours following radiation exposure.

- 90 -

67. The method of claim 66, wherein the administering comprises administering the targeting ligand about 4 hours to about 24 hours following radiation exposure.

68. The method of claim 60, wherein the subject is a warm-blooded vertebrate.

69. The method of claim 68, wherein the subject is a human.

70. The method of claim 60, wherein the one or more targeting ligands comprises a peptide comprising an amino acid sequence of any one of SEQ ID NOs:1-5, or combinations thereof.

71. The method of claim 60, wherein the one or more targeting ligands comprises a peptide comprising an amino acid sequence of any one of SEQ ID NOs:1-13, or combinations thereof.

72. The method of claim 60, wherein the one or more targeting ligands comprises a single chain antibody comprising:

- (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:18 or 20;
- (b) a polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO:18 or 20;
- (c) a polypeptide encoded by a nucleotide sequence of SEQ ID NO:17 or 19;
- (d) a polypeptide encoded by a nucleotide sequence substantially identical to SEQ ID NO:17 or 19; or
- (e) combinations thereof.

73. The method of claim 60, wherein the detectable label is detectable *in vivo*.

74. The method of claim 73, wherein the detectable label comprises a label that can be detected using magnetic resonance imaging, scintigraphic imaging, ultrasound, or fluorescence.

75. The method of claim 74, wherein the label that can be detected using scintigraphic imaging comprises a radionuclide label.

76. The method of claim 75, wherein the radionuclide label is <sup>131</sup>I or <sup>99m</sup>Tc.

77. The method of claim 75, wherein the detecting comprises detecting the radionuclide label using positron emission tomography, single photon emission computed tomography, gamma camera imaging, or rectilinear scanning.

5        78. The method of claim 60, wherein the tumor is a primary or a metastasized tumor.

79. The method of claim 60, wherein the tumor comprises a tumor selected from the group consisting of bladder carcinoma, breast carcinoma, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, gastric  
10        sarcoma, glioma, lung carcinoma, lymphoma, melanoma, multiple myeloma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, stomach carcinoma, a head, a neck tumor, and a solid tumor.

80. The method of claim 79, wherein the tumor is selected from the group consisting of a glioma, a melanoma, and a lung carcinoma.

15        81. The method of claim 60, further comprising simultaneously detecting two or more tumors in a subject.

82. The method of claim 81, wherein the two or more tumors in a subject comprise two or more tumor types.

83. A method for diagnosing a tumor in a subject comprising:

- 20        (a) exposing a suspected tumor to ionizing radiation;  
          (b) isolating the suspected tumor, or fraction thereof;  
          (c) contacting the suspected tumor with one or more targeting ligands identified by *in vivo* panning, wherein the one or more targeting ligands binds to an irradiated tumor, and wherein the one or more targeting ligands comprises a detectable label;  
25        and  
          (d) detecting the detectable label, whereby the tumor is diagnosed.

84. The method of claim 83, wherein the exposing comprises  
30        exposing the tumor to less than about 2 Gy ionizing radiation.

85. The method of claim 84, wherein the exposing comprises exposing the tumor to about at least about 2 Gy ionizing radiation.

86. The method of claim 85, wherein the exposing comprises exposing the tumor to about 10 Gy to about 20 Gy ionizing radiation.

87. The method of claim 83, wherein the subject is a warm-blooded vertebrate.

5        88. The method of claim 87, wherein the subject is a human.

89. The method of claim 83, wherein the isolating comprises biopsing a tissue suspected of comprising a tumor.

90. The method of claim 83, wherein the isolating is performed prior to or subsequent to exposing the tissue to ionizing radiation.

10       91. The method of claim 83, wherein the one or more targeting ligands binds to an irradiated tumor.

92. The method of claim 83, wherein the one or more targeting ligands comprises a peptide comprising an amino acid sequence of any one of SEQ ID NOs:1-5, or combinations thereof.

15       93. The method of claim 83, wherein the one or more targeting ligands comprises a single chain antibody comprising:

(a) a polypeptide comprising an amino acid sequence of SEQ ID NO:18 or 20;

20       (b) a polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO:18 or 20;

(c) a polypeptide encoded by a nucleotide sequence of SEQ ID NO:17 or 19;

(d) a polypeptide encoded by a nucleotide sequence substantially identical to SEQ ID NO:17 or 19; or

25       (e) combinations thereof.

94. The method of claim 83, wherein the detectable label comprises a fluorophore, an epitope, or a radiolabel.

95. The method of claim 83, wherein the tumor is a primary or a metastasized tumor.

30       96. The method of claim 83, wherein the tumor comprises a tumor selected from the group consisting of bladder carcinoma, breast carcinoma, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, gastric

- 93 -

sarcoma, glioma, lung carcinoma, lymphoma, melanoma, multiple myeloma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, stomach carcinoma, a head tumor, a neck tumor, and a solid tumor.

5           97. The method of claim 96, wherein the tumor is selected from the group consisting of a glioma, a melanoma, and a lung carcinoma.

98. A method for x-ray-guided delivery of a therapeutic composition, a diagnostic composition, or a combination thereof, to a tumor in a subject, the method comprising:

- 10           (a) exposing the tumor to ionizing radiation; and  
             (b) administering to the subject a therapeutic composition, a diagnostic composition, or a combination thereof, wherein the composition comprises one or more targeting ligands identified by *in vivo* panning; whereby the therapeutic composition, the  
15           diagnostic composition, or the combination thereof, is selectively targeted to the tumor.

99. The method of claim 98, wherein the tumor is a primary or a metastasized tumor.

100. The method of claim 98, wherein the tumor is selected from a  
20           tumor selected from the group consisting of bladder carcinoma, breast carcinoma, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, gastric sarcoma, glioma, lung carcinoma, lymphoma, melanoma, multiple myeloma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, stomach carcinoma, a head tumor, a neck tumor, and a solid  
25           tumor.

101. The method of claim 100, wherein the tumor is selected from the group consisting of a glioma, a melanoma, and a lung carcinoma.

102. The method of claim 98, wherein the exposing comprises exposing the tumor to less than about 2 Gy ionizing radiation.

30           103. The method of claim 102, wherein the exposing comprises exposing the tumor to at least about 2 Gy ionizing radiation.

104. The method of claim 103, wherein the exposing comprises exposing the tumor to about 10 Gy to about 20 Gy ionizing radiation.

105. The method of claim 98, wherein the administering comprises administering the targeting ligand by intravascular provision.

5 106. The method of claim 98, wherein the administering comprises administering the targeting ligand subsequent to radiation exposure.

107. The method of claim 106, wherein the administering comprises administering the targeting ligand 0 hours to about 24 hours following radiation exposure.

10 108. The method of claim 107, wherein the administering comprises administering the targeting ligand about 4 hours to about 24 hours following radiation exposure.

109. The method of claim 98, wherein the subject is a warm-blooded vertebrate.

15 110. The method of claim 109, wherein the subject is a human.

111. The method of claim 98, wherein the therapeutic composition further comprises a radionuclide, a cytotoxin, a therapeutic gene, or a chemotherapeutic agent.

20 112. The method of claim 98, wherein the diagnostic composition further comprises a detectable label.

113. The composition of claim 112, wherein the detectable label is detectable *in vivo*.

25 114. The method of claim 113, wherein the detectable label comprises a label that can be detected using magnetic resonance imaging, scintigraphic imaging, ultrasound, or fluorescence.

115. The method of claim 114, wherein the label that can be detected using scintigraphic imaging comprises a radionuclide label.

116. The method of claim 115, wherein the radionuclide label is  $^{131}\text{I}$  or  $^{99\text{m}}\text{Tc}$ .

30 117. The method of claim 115, further comprising detecting the radionuclide label using positron emission tomography, single photon

emission computed tomography, gamma camera imaging, or rectilinear scanning.

118. The method of claim 98, wherein the one or more targeting ligands comprises a peptide comprising an amino acid sequence of any one of SEQ ID NOs:1-5, or combinations thereof.

119. The method of claim 98, wherein the one or more targeting ligands comprises a single chain antibody comprising:

- (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:18 or 20;
- 10 (b) a polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO:18 or 20;
- (c) a polypeptide encoded by a nucleotide sequence of SEQ ID NO:17 or 19;
- (d) a polypeptide encoded by a nucleotide sequence substantially identical to SEQ ID NO:17 or 19; or
- 15 (e) combinations thereof.

120. The method of claim 98, wherein the selective targeting comprises targeting to an irradiated tumor in the absence of targeting to a non-irradiated tumor, to non-irradiated normal tissue, and to irradiated normal tissue.

121. A method for identifying a radiation-induced target molecule comprising:

- (a) providing a targeting ligand identified by in vivo panning, wherein the targeting ligand binds to an irradiated tumor;
- 25 (b) exposing the targeting peptide to one or more candidate target molecules; and
- (c) determining selective binding of the one or more candidate target molecules to the targeting ligand, whereby a radiation-induced target molecule is identified.

122. The method of claim 121, wherein the targeting ligand comprises a peptide comprising an amino acid sequence of any one of SEQ ID NOs:1-5, or combinations thereof.

- 96 -

123. The method of claim 121, wherein the targeting ligands comprises a single chain antibody comprising:

- (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:18 or 20;
- 5 (b) a polypeptide comprising an amino acid sequence substantially identical to SEQ ID NO:18 or 20;
- (c) a polypeptide encoded by a nucleotide sequence of SEQ ID NO:17 or 19;
- 10 (d) a polypeptide encoded by a nucleotide sequence substantially identical to SEQ ID NO:17 or 19; or
- (e) combinations thereof.

124. The method of claim 121, wherein the radiation-induced target molecule comprises a molecule present on a tumor cell, an endothelial cell associated with tumor vasculature, or a blood component.

- 15 125. A target molecule identified by the method of claim 121.

SEQUENCE LISTING

<110> Vanderbilt University

Hallahan, Dennis

Qu, Shimian

<120> IN VIVO PANNING FOR LIGANDS TO RADIATION-INDUCED MOLECULES

<130> 1242/47

<150> US 60/328123

<151> 2001-10-18

<160> 20

<170> PatentIn version 3.0

<210> 1

<211> 8

<212> PRT

<213> synthetic construct

<400> 1

Asn His Val Gly Gly Ser Ser Val  
1 5

<210> 2

<211> 10

<212> PRT

<213> synthetic construct

<400> 2

Asn Ser Leu Arg Gly Asp Gly Ser Ser Val  
1 5 10

<210> 3

<211> 10

<212> PRT

<213> synthetic construct

<400> 3

Asn Ser Val Arg Gly Ser Gly Ser Gly Val  
1 5 10

<210> 4

<211> 7

<212> PRT

<213> synthetic construct

<400> 4

Asn Ser Val Gly Ser Arg Val  
1 5

<210> 5

<211> 9

<212> PRT

<213> synthetic construct

<400> 5

Ser Leu Arg Gly Asp Gly Ser Ser Val  
1 5

<210> 6

<211> 7

<212> PRT

<213> synthetic construct

<400> 6

Arg Gly Asp Gly Ser Ser Val  
1 5

<210> 7

<211> 4

<212> PRT

<213> synthetic construct

<400> 7

Gly Ser Arg Val

1

<210> 8

<211> 4

<212> PRT

<213> synthetic construct

<220>

<221> MISC\_FEATURE

<222> (1)..(4)

<223> X is any amino acid

<400> 8

Gly Ser Xaa Val

1

<210> 9

<211> 8

<212> PRT

<213> synthetic construct

<220>

<221> MISC\_FEATURE

<222> (1)..(8)

<223> X is any amino acid

<400> 9

Asn Ser Xaa Arg Gly Xaa Gly Ser

1

5

<210> 10

<211> 3

<212> PRT

<213> synthetic construct

<400> 10

Asn Ser Val

1

<210> 11

<211> 4

<212> PRT

<213> synthetic construct

<220>

<221> MISC\_FEATURE

<222> (1)..(4)

<223> X is any amino acid

<400> 11

Asn Ser Xaa Arg

1

<210> 12

<211> 4

<212> PRT

<213> synthetic construct

<220>

<221> MISC\_FEATURE

<222> (1)..(4)

<223> X is any amino acid

<400> 12

Asn Xaa Val Gly

1

<210> 13

<211> 4

<212> PRT

<213> synthetic construct

<400> 13

Gly Ser Ser Val  
1

<210> 14

<211> 20

<212> DNA

<213> T7 bacteriophage

<400> 14

agcggaccag attatcgcta

20

<210> 15

<211> 19

<212> DNA

<213> T7 bacteriophage

<400> 15

aaccctcaag acccgttta

19

<210> 16

<211> 12

<212> PRT

<213> synthetic construct

<400> 16

His His Cys Gly Gly Ala Lys Gln Ala Gly Asp Val  
1 5 10

&lt;210&gt; 17

&lt;211&gt; 726

&lt;212&gt; DNA

&lt;213&gt; synthetic construct

&lt;221&gt; CDS

&lt;222&gt; (1)..(726)

&lt;400&gt; 17

```

atg gcc cag gtg aaa ctg cag cag tct ggg gct gag ctt gtg atg cct      48
Met Ala Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Met Pro
1          5          10          15

ggg gct tca gtg aag atg tcc tgc aag gct tct ggc tac aca ttc act      96
Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
          20          25          30

gac tac tgg atg cac tgg gtg aag cag agg cct gga caa ggc ctt gag      144
Asp Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
          35          40          45

tgg atc gga gcg att gat act tct gat agt tat act agc tac aat caa      192
Trp Ile Gly Ala Ile Asp Thr Ser Asp Ser Tyr Thr Ser Tyr Asn Gln
          50          55          60

aag ttc aag ggc aag gcc aca ttg act gta gac gaa tcc tcc agc aca      240
Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Glu Ser Ser Ser Thr
          65          70          75          80

gcc tac atg cag ctc agc agc ctg aca tct gag gac tct gcg gtc tat      288
Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
          85          90          95

tac tgt gca aga aga ggc tac tat agc gca ttt gat tac tgg ggc caa      336
Tyr Cys Ala Arg Arg Gly Tyr Tyr Ser Ala Phe Asp Tyr Trp Gly Gln
          100          105          110

ggg act acg gtc acc gtc tcc tca ggt gga ggc ggt tca ggc gga ggt      384
Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
          115          120          125

ggc tct ggc ggt ggc gga tcg gac att gag ctc acc cag tct cca aca      432
Gly Ser Gly Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Thr
          130          135          140

acc atg gct gca tct cca gga gag aag gtc acc atc acc tgc cgt gcc      480
Thr Met Ala Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Arg Ala
          145          150          155          160

agc tca agt gta agc tac atg cac tgg ttc cag cag aag tca ggc acc      528
Ser Ser Ser Val Ser Tyr Met His Trp Phe Gln Gln Lys Ser Gly Thr
          165          170          175

```

7/10

tcc ccc aaa ccc tgg att tat gac aca tcc aag ctg gct tct gga gtc 576  
 Ser Pro Lys Pro Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val  
                   180                  185                  190

cca gat cgc ttc agt ggc agt ggg tct ggg acc tct tat tct ctc aca 624  
 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr  
                   195                  200                  205

atc agc tcc atg gag gct gaa gat gct gct act tat tac tgt ctg cag 672  
 Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gln  
                   210                  215                  220

agg agt agt tac ccg tac acg ttt gga gct ggc acc aag ctg gaa atc 720  
 Arg Ser Ser Tyr Pro Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile  
                   225                  230                  235                  240

aaa cgg 726  
 Lys Arg

&lt;210&gt; 18

&lt;211&gt; 242

&lt;212&gt; PRT

&lt;213&gt; synthetic construct

&lt;400&gt; 18

Met Ala Gln Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Met Pro  
 1                  5                  10                  15

Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr  
                   20                  25                  30

Asp Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu  
                   35                  40                  45

Trp Ile Gly Ala Ile Asp Thr Ser Asp Ser Tyr Thr Ser Tyr Asn Gln  
                   50                  55                  60

Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Glu Ser Ser Ser Thr  
                   65                  70                  75                  80

Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr  
                   85                  90                  95

Tyr Cys Ala Arg Arg Gly Tyr Tyr Ser Ala Phe Asp Tyr Trp Gly Gln  
                   100                  105                  110

Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly  
                   115                  120                  125

Gly Ser Gly Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Thr  
                   130                  135                  140

8/10

Thr Met Ala Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Arg Ala  
 145 150 155 160  
 Ser Ser Ser Val Ser Tyr Met His Trp Phe Gln Gln Lys Ser Gly Thr  
 165 170 175  
 Ser Pro Lys Pro Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val  
 180 185 190  
 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr  
 195 200 205  
 Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gln  
 210 215 220  
 Arg Ser Ser Tyr Pro Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile  
 225 230 235 240  
 Lys Arg

&lt;210&gt; 19

&lt;211&gt; 726

&lt;212&gt; DNA

&lt;213&gt; synthetic construct

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(726)

&lt;400&gt; 19

atg gcc cag gtc aag ctg cag cag tca gga cct gag ctg gta aag cct	48
Met Ala Gln Val Lys Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro	
1 5 10 15	
ggg gct tca gtg aag atg tcc tgc aag gct tct gga tac aca ttc act	96
Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr	
20 25 30	
agc tat gtt atg cac tgg gtg aag cag aag cct ggg cag ggc ctt gag	144
Ser Tyr Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu	
35 40 45	
tgg att gga tat att aat cct tac aat gat ggt act aag tac aat gag	192
Trp Ile Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu	
50 55 60	
aag ttc aaa ggc aag gcc gca ctg act tca gac aaa tcc tcc agc aca	240
Lys Phe Lys Gly Lys Ala Ala Leu Thr Ser Asp Lys Ser Ser Ser Thr	
65 70 75 80	

9/10

```

gcc tac atg gag ctc agc agc ctg acc tct gag gac tct gcg gtc tat      288
Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
                        85                      90                      95

tac tgt gca aga ttt ggt aac tac ggt gct ttg gac tac tgg ggc caa      336
Tyr Cys Ala Arg Phe Gly Asn Tyr Gly Ala Leu Asp Tyr Trp Gly Gln
                        100                      105                      110

ggg acc acg gtc acc gtc tcc tca ggt gga ggc ggt tca ggc gga ggt      384
Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
                        115                      120                      125

ggc tct ggc ggt ggc gga tcg gac att gag ctc acc cag tct cca aca      432
Gly Ser Gly Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Thr
                        130                      135                      140

atc atg tct gca tct cca ggg gag aag gtc acc ata acc tgc agt gcc      480
Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Ser Ala
145                      150                      155                      160

agc tca agt gta agt tac atg cac tgg ttc cag cag aag cca ggc act      528
Ser Ser Ser Val Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Thr
                        165                      170                      175

tct ccc aaa ccc tgg att tat ggc aca tcc aac ctg gct tct gga gtc      576
Ser Pro Lys Pro Trp Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val
                        180                      185                      190

cct gtt cgc ttc agt ggc agt gga tct ggg acc tct tat tct ctc aca      624
Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr
                        195                      200                      205

atc agc agc atg gag gct gaa gat gct gcc act tat tac tgt caa cag      672
Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln
210                      215                      220

tgg agt agt tac cca ctc acg ttc gga ggg ggg acc aag ctg gaa ata      720
Trp Ser Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
225                      230                      235                      240

aaa cgg
Lys Arg                                                                726

```

&lt;210&gt; 20

&lt;211&gt; 242

&lt;212&gt; PRT

&lt;213&gt; synthetic construct

&lt;400&gt; 20

```

Met Ala Gln Val Lys Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro
1          5                      10                      15

```

10/10

Gly	Ala	Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	20	25	30	
Ser	Tyr	Val	Met	His	Trp	Val	Lys	Gln	Lys	Pro	Gly	Gln	Gly	Leu	Glu	35	40	45	
Trp	Ile	Gly	Tyr	Ile	Asn	Pro	Tyr	Asn	Asp	Gly	Thr	Lys	Tyr	Asn	Glu	50	55	60	
Lys	Phe	Lys	Gly	Lys	Ala	Ala	Leu	Thr	Ser	Asp	Lys	Ser	Ser	Ser	Thr	65	70	75	80
Ala	Tyr	Met	Glu	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	85	90	95	
Tyr	Cys	Ala	Arg	Phe	Gly	Asn	Tyr	Gly	Ala	Leu	Asp	Tyr	Trp	Gly	Gln	100	105	110	
Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	115	120	125	
Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Ile	Glu	Leu	Thr	Gln	Ser	Pro	Thr	130	135	140	
Ile	Met	Ser	Ala	Ser	Pro	Gly	Glu	Lys	Val	Thr	Ile	Thr	Cys	Ser	Ala	145	150	155	160
Ser	Ser	Ser	Val	Ser	Tyr	Met	His	Trp	Phe	Gln	Gln	Lys	Pro	Gly	Thr	165	170	175	
Ser	Pro	Lys	Pro	Trp	Ile	Tyr	Gly	Thr	Ser	Asn	Leu	Ala	Ser	Gly	Val	180	185	190	
Pro	Val	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Ser	Tyr	Ser	Leu	Thr	195	200	205	
Ile	Ser	Ser	Met	Glu	Ala	Glu	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	210	215	220	
Trp	Ser	Ser	Tyr	Pro	Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	225	230	235	240
Lys	Arg																		